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General introduction
Bladder cancer is the fourth most common malignancy in men and the eighth
most common malignancy in women in Europe and the United States. Each
year approximately 20 new cases per 100.000 persons are diagnosed with
bladder cancer, resulting in 6 per 100.000 persons dying from this disease
annually. It develops more predominantly in males than in females with a sex
ratio of 3 to 1 and has a peak incidence in the seventh decade of life.
A number of etiological factors are associated with the development of bladder
cancer, such as chronic urinary tract infections, pelvic radiotherapy,
chemotherapy with cyclophosphamide and occupational exposure to aromatic
amines. However, cigarette smoking is by far the most important risk factor
increasing the chance of bladder cancer two to four times and accounting for
30 to 50% of all bladder carcinomas.
The majority (90-95%) of these cancers are urothelial cell carcinomas (UCC) of
various histologic grades (WHO I to III). Other histologic types are squamous
cell carcinoma (SCC) (2-4%) and adenocarcinoma (1-2%). In Egypt, and other
countries with endemic spread of the parasite Schistosoma haematobium, SCC
is the most frequent histological subtype found.
The most important symptom that raises suspicion for a bladder tumor is
macroscopic (or microscopic) haematuria. Haematuria is mostly painless and
often intermittent, which causes patients delay frequently. Other symptoms,
caused by irritation of the bladder by the tumor, are frequency and urgency.
The diagnosis of bladder tumor is made by urethrocystoscopy (UCS) and
cytological analysis of urine or bladder barbotage material.
In case of a bladder tumor on UCS a transurethral resection (TUR) is planned.
The objectives of the TUR are to completely remove the tumor, or if not
possible to obtain sufficient material, for histopathological diagnosis and tumor
staging.
Approximately 75 % of the patients with UCC present with superficial tumors
and 1 to 3% is associated with an upper urinary tract tumor at initial diagnosis.
The superficial lesions appear as papillary tumors limited to the mucosa (stage
Ta) or invading the lamina propria (T1) or as flat carcinoma in situ (CIS) with
diffuse malignant cells confined to the mucosa. The likelihood that superficial
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bladder cancer will recur is about 70% in 5 years with a peak incidence in the
first year after initial treatment. As many as 30% of these recurrent tumors
present with a higher histologic grade and about 10% progress to muscle-
invasive tumor, creating a risk for death.
The remaining 20% to 30% of neoplasms are muscle-invasive (≥T2) and/or
metastatic at the time of initial presentation. Stage T2 tumors extend into the
superficial (T2a) or deep (T2b) muscularis propria. Stage T3 tumors extend
either microscopically (T3a) or macroscopically (T3b) in the perivesical fat.
Stage T4 tumors extend into contiguous organs. About 50% of patients with
muscle-invasive bladder cancer already have occult distant metastases, which
limits the efficacy of therapy. Most of these patients develop clinical evidence
of metastases within 1 year and succumb within 2 years of initial diagnosis. The
5-year survival with surgery alone is about 45% for T2N0M0 and
approximately 35% for T3N0M0 bladder cancer patients. Patients with
advanced disease (T4N0M0, TanyN+M0, TanyN0M+, TanyN+M+) can
expect a short survival. The 5-year survival rate for this stage is only 10%.
Invasion of tumor cells into superficial lymphatic and vascular vessels just
beneath the lamina propria may cause metastatic spread of bladder cancer. The
bladder lymphatics drain to perivesical, external iliac, hypogastric and common
iliac lymph nodes. Lymphatic spread is rare in stage T1 tumors and found in
24% of the muscle-invasive tumors. Lymph node (LN) metastases in patients
with T2 tumors are in more than 95% confined to the true pelvis. In patients
with T3 or T4 tumors LN metastases are seen more often (15%) outside the
common boundaries for standard LN dissection, namely at or above the aortic
bifurcation. Haematogenous spread of bladder carcinoma is infrequent. If they
occur, these metastases usually appear in lungs, bones, and liver. Bony
metastases are predominantly seen in pelvic bones, upper femora, ribs and
skull.
Once the diagnosis has been confirmed by cystoscopy, transurethral surgery
and histologic evaluation, the stage and grade of the tumor according to the
TNM (tumor, node, metastases) staging and WHO-grading system must be
determined. Staging is important because it indicates the most appropriate
treatment, provides a guide to the likely prognosis and permits assessment of
the response to therapy.
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Patients with pTaG1 have a low recurrence rate and no adjuvant treatment, but
one immediate instillation with a chemotherapeutic agent to lower the
recurrence rate in the first year, is an option. In recurrent or multifocal low risk
tumors adjuvant chemotherapy, in an attempt to reduce recurrences, has
become common practice. Patients with intermediate or high risk superficial
UCC (pTaG2-pT1G3) are treated with intravesical instillations with BCG
(bacillus Calmette Guérin) to delay recurrence and prevent progression.
Patients with persistent high risk superficial UCC (pT1G3 or CIS) are
candidates for aggressive therapy such as extended pelvic lymph node
dissection and radical cystectomy. The standard treatment for patients with
organ confined disease (T2N0M0, T3N0M0) is extended pelvic lymph node
dissection with radical cystectomy. The only chance for improvement in
survival in patients with advanced disease is chemotherapy.
Aims of the study
The author’s interest for bladder carcinoma and neobladders was initiated
during a visit at the Urology and Nephrology Center in Mansoura, Egypt.
Mansoura is located in the centre of the Nile Delta. The people living in this
region are strongly dependent on the water from this river. Unfortunately, the
river Nile is contaminated with Schistosoma Haematobium, giving the infected
people an increased risk for the development of SCC of the bladder. The high
incidence of bladder cancer in the Nile Delta and highly motivated local
urologists made the hospital in Mansoura a centre of expertise, with more than
100 cystectomies and Mansoura neobladders per year. Shortly after this visit
the technique of the Mansoura neobladder was introduced in the Netherlands.
The first Mansoura was created by the department of urology of the Central
Military Hospital Utrecht (head P.Dik).
The author started the research for this thesis as urologist in training at the
University Medical Centre St Raboud, Nijmegen in 2000.
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The aims of the study can be summarized as follows:
Patients with muscle-invasive bladder cancer can be divided in two groups.
One, patients with a history of superficial bladder cancer: the progressive
group and the other, patients without this history: the primary group. In daily
clinical practice we had the impression that patients in the progressive group
had a worse prognosis than patients in the primary group. A retrospective
study, as described in chapter 2, was performed to test if there is a difference in
survival between these two patient groups.
1. To study the difference in prognosis between muscle-invasive
bladder cancer patients with and without a history of superficial
bladder cancer (chapter 2).
The ideal situation would be if we could identify tumors with aggressive
potential with accurate prognostic factors. Traditional prognostic factors to
predict clinical outcome of superficial bladder carcinoma are tumor size, stage
and grade, concomitant CIS, tumor recurrence rate and multiplicity. It is
generally accepted that these prognostic factor are not accurate enough to
predict the biological behaviour of bladder tumors and to define the risk of
tumor recurrence and disease progression. With a better understanding of the
cell cycle and cell to cell and cell to extracellular matrix interactions, progress is
being made to identify and characterize other potential prognostic markers for
UCC of the bladder. The cell cycle regulatory proteins p53 and p27Kip1, and the
cell adhesion complex protein α-catenin are considered potentially useful
prognostic markers. The aim of the study presented in chapter 3 is to evaluate
these potential prognostic markers for bladder carcinoma.
2. To determine the prognostic value of cell cycle regulatory proteins
(p53, p27Kip1) and cell adhesion complex protein (α-catenin) in
progressive bladder carcinoma (chapter 3).
As stated in the introduction, in patients with clinically invasive but localised
disease the survival is approximately 50% due to microscopic metastasis at the
time of initial presentation. The rapidity with which silent metastases make
themselves evident is impressive. The majority is detectable within the first
post-cystectomy year and most patients die several months after the diagnosis
of metastases. There is a need to identify patients with microscopic metastases
Chapter 1
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so they can be treated (with chemotherapy) in an early stage. We aimed to
determine the prognostic value of angiolymphatic invasion (ALI) in these
patients, because ALI is a positive predictor for microscopic metastasis in
several malignancies.
3. To evaluate the prognostic value of perineural and angiolymphatic
invasion in advanced non-metastasized bladder cancer (chapter 4).
During the last decades radical cystectomy with urinary diversion or bladder
replacement has emerged as the gold standard treatment for muscle-invasive
bladder carcinoma. Many different methods of bladder substitution have been
developed in the attempt to achieve the goal of a neobladder that functions as
well as a normal bladder. The ideal neobladder substitute should have adequate
capacity, store urine at low pressure, preserve continence, evacuate via the
urethra with minimal residual urine, preserve the upper urinary tract and renal
function, and cause no or minimal metabolic disturbance. Various segments of
small and large bowel have been used for neobladder construction. There are
clear differences between ileum and colon in regard to metabolic
consequences. The subjective success of an orthotopic bladder replacement
largely depends on the degree of continence that the patient is able to achieve.
In a comparative study we aimed to compare the functionality between small
and large bowel neobladders.
4. To compare urodynamic and continence parameters between
orthotopic sigmoid and ileal neobladder (chapter 5).
Mucus production by mucoid secretory cells in the small bowel that is used for
urinary diversion or continent ileal reservoirs is well known. Mucinous
obstruction of the reconstructed urinary tract is published in case reports.
Mucus is composed of mucins. Mucin monomers polymerize by creating
disulphide bonds into large polymers. N-acetyl-L-cysteine (NAC) (Fluimucil®)
can reduce these bonds creating smaller, less viscous units. Since NAC is used
in patients with ileal neobladders in our clinic routinely, complications like
obstructive mucus are never seen. The effect of NAC on ileal neobladder
mucus is described in chapter 6.
5. To investigate the effect of N-acetyl-L-cysteine (Fluimucil®) on
the viscosity of ileal neobladder mucus (chapter 6).
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Without treatment, patients with locally advanced or metastatic bladder
carcinoma die from their disease. Before the development of effective
chemotherapy, median survival rarely exceeded 6 months. With combination
chemotherapy, median survival times of more than 3 years for complete
responders and about 1 year for partial responders can be achieved. The
median survival for non-responders is poor. Assessment of the efficacy of
chemotherapy is important so that nonresponders can be identified in an early
stage. These patients can be protected from unnecessary additional treatment
with additional side effects and loss of quality of life. We aimed to identify
nonresponders early with Magnetic Resonance Imaging (MRI).
6. To evaluate chemotherapy efficacy with Magnetic Resonance
Imaging in patients with regionally metastatic or unresectable
carcinoma of the bladder (chapter 7).
Once the diagnosis has been confirmed, the size and extent of the tumor, or
stage of the cancer, must be determined. Staging indicates the most appropriate
treatment and provides a guide to the prognosis. Since imaging plays an
important role in bladder cancer staging the invitation to write a chapter about
this issue in a textbook of bladder cancer was accepted with gratitude. This
chapter is presented in chapter 8.
7. To review the use of imaging modalities in the assessment of
bladder cancer stage (chapter 8).
Finally, in chapter 9, a summary of this thesis and future perspectives are
presented in English and in Dutch.
Chapter 2
Prognosis of muscle invasive bladder cancer:
difference between primary and progressive tumors
and implications for therapy
European Urology, 2004; 45: 292-6.
B.Ph. Schrier, M.P. Hollander, B.W.G. van Rhijn, L.A.L.M. Kiemeney,
J.A. Witjes
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Abstract
Objective: To evaluate the difference in prognosis between progressive and
primary muscle-invasive bladder cancer.
Materials and Methods: From 1986 to 2000, 74 patients with progressive muscle-
invasive bladder cancer were identified. Eighty-nine patients with primary
muscle-invasive bladder cancer were frequency matched for stage to these
patients with progressive disease. Baseline data including patient and tumor
characteristics were collected at the time of diagnosis of the muscle-invasive
tumor. Duration of survival was defined as time from muscle-invasive bladder
cancer diagnosis until disease-specific death. Kaplan-Meier curves were drawn
to determine the difference in prognosis between the two study groups. To
adjust for potential residual confounding due to differences in treatment, 4
subgroups (T2/3, T4, N+ and M+) were constructed according to the TNM
classification. In order to see whether age and gender had any effect on
outcome, the four stage groups, age and gender were entered in a Cox’s
proportional hazard regression model.
Results: The 3-year bladder cancer specific survival was 65% in the primary
group and 37% in the progressive group (P = 0.0015). Kaplan Meier curves of
different stage groups showed a clear trend towards a better prognosis in the
patients with pT2/3 primary tumor or N+ primary tumor at baseline. Cox’s
regression analysis demonstrated that age and gender had no influence on
bladder specific survival.
Conclusions: Patients with muscle-invasive bladder cancer and a history of
superficial bladder cancer have a worse prognosis than patients with primary
muscle-invasive bladder cancer.
Introduction
Urothelial cell carcinoma (UCC) of the urinary bladder can present as a
superficial or as a muscle-invasive lesion. The majority of patients
(approximately 75%) present with relatively benign superficial tumors, which
are limited to the mucosa (Ta) or the lamina propria (T1) [1]. Carcinoma in situ
(Cis) can also be considered superficial. However, Cis tends to behave more
aggressively and is often found in association with high-grade superficial
tumors. Tumor recurrence with superficial tumor is quite common and can be
Difference in prognosis between primary and progressive invasive bladder cancer
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as high as 50% to 70% following therapy [2,3]. About 30% of these recurrent
tumors will progress to a higher grade or stage, with approximately 10% of
these recurrent cancers progressing to a muscle-invasive disease [4,5]. On the
other hand, about 15% of patients who present with muscle-invasive tumors
have a history of progression from superficial carcinoma. However, most of
the diagnosed cases of muscle-invasive bladder cancer (80% to 90%) present
without prior history of superficial disease i.e. primary invasive bladder cancer.
Patients with primary and progressive muscle-invasive bladder cancer are
treated equally in normal daily practice assuming a similar cancer-specific
survival for both groups. However, to our knowledge, studies on this subject
do not exist. In addition, timing of radical treatment (cystectomy) for patients
with high risk superficial disease remains a controversial issue. Therefore, we
performed a retrospective study to determine the difference in survival
between these two patient populations.
Patients and methods
A retrospective study was performed in patients treated for muscle-invasive
bladder cancer at the department of urology of the UMC (University Medical
Centre) St. Radboud Nijmegen and the department of urology of UMC
Dijkzigt Rotterdam. Medical records of patients treated between 1986 and
2000 were reviewed. Seventy-four patients treated for muscle-invasive bladder
cancer, who had shown progression from a superficial tumor, were identified.
Diagnosis of superficial bladder cancer was made by histological judgment of
material acquired by fractionated transurethral resection (TUR-T) of all
obvious tumor. All tumors were UCC. Muscle was present in all specimens and
no tumor invasion was found. Tumors were evaluated using WHO grades 1, 2
and 3. Pathological stage was classified according the TNM staging system [6].
All patients received additional intravesical therapy, consisting of at least two
courses of bacillus Calmette-Guérin (BCG) or maintenance BCG. At three
months all patients were checked for early recurrence or residual tumor.
Patients with invasive tumor at this point were excluded in order to prevent
misclassification of invasive tumors, missed during the initial TUR-T. Patients
with upper urinary tract tumors were also excluded. Eighty-nine patients with
primary muscle-invasive bladder cancer were frequency matched for stage to
the patients with progressive disease.
Patients with stage II (T2N0-1M0) and III (T3N0-1M0) underwent extended
pelvic lymph node dissection and radical cystectomy. Time to cystectomy was
less than 10 weeks for all patients. No patients with stage II or III were treated
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by an organ preserving approach. Chemotherapy was offered to patients with
stage IV (T4N0M0, TanyN2-3M0, TanyN0M1-3, TanyN2-3M1-3).
Baseline data including patient and tumor characteristics were collected at the
time of diagnosis of the muscle-invasive tumor. Primary endpoint of the study
was disease-specific survival, defined as time from muscle-invasive bladder
diagnosis until bladder cancer specific death. Patients known to be alive or lost
to follow-up were censored at the last contact date.
To analyze possible differences between the de novo and the progressive
group survival curves were calculated by the Kaplan-Meier product limit
method. Differences between survival curves were assessed with the log rank
test. Survival curves were drawn for the total study population and the four
stage groups separately in order to look for possible effect modification.
Multivariate analysis using proportional hazards regression modeling was used
to exclude any confounding effect of age, gender and stage group. All analyses
were performed using the SPSS software package (Version 9.0, Chicago, IL).
Results
A total of 163 patients were included in the study, 99 from the UMC Nijmegen
and 64 from the UMC Rotterdam. Of the total study population, 89 cases
showed a primary invasive bladder tumor and 74 patients had a history of
treated superficial disease. One patient with a primary invasive bladder tumour
and 2 patients with a progressive tumor were lost to follow-up. The last stage
of the superficial tumor before progression to muscle-invasive bladder
carcinoma was pTaG1 in 6, pTaG2 in 22, pTaG3 in 3, pT1G2 in 17, pT1G3 in
20 and pTis in 6 patients.
Table 2.1. Baseline characteristics of the study group (n = 163)
Primary tumors Progressive tumors
N 89 74
Mean Age (years) 63.3 68.5
TNM (n,%)
pT 2/3 48 (54%) 42 (57%)
pT 4 7 (8%) 3 (4%)
N+ 27 (30%) 21 (28%)
M+ 7 (8%) 8 (11%)
Gender (n,%)
Male 65 (73%) 60 (81%)
Female 24 (27%) 14 (19%)
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Baseline characteristics of the study population are shown in Table 2.1. The
mean age of the progressive group, as well as the percentage of male patients is
slightly higher than in the primary group. The distribution of the stage groups
pT2/3, N+ and M+ is more or less comparable for the primary and the
progressive tumors. The primary group has almost twice as much pT4 tumors,
but the numbers are small.
Follow-up (years) after invasive disease
Fig. 2.1. Kaplan-Meier survival curve comparing primary (--) and progressive (-) study
group.
Figure 2.1 shows the Kaplan-Meier survival curve comparing the disease
specific survival for the primary and progressive study groups. The primary
group has a statistically significant better disease-specific survival than the
progressive group (p = 0.0015). The 3- and 5-year survival rates are 67% (95%
confidence interval [CI] 57 to 77%) and 55% (95% CI 43 to 67%) respectively
Chapter 2
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for patients with a primary invasive tumor and 37% (95% CI 24 to 50%) and
28% (95% CI 15 to 41%) respectively for patients with a progressive invasive
tumor. After 3 years 17 patients in the progressive group and 42 in the primary
group were alive. The number of patients alive after 5 years decreased to 9 in
the progressive and 21 in the primary group.
In the pT2/3 group, the survival curve shows a similar pattern as the curve for
the total study population (p = 0.001) (Figure 2).
Follow-up (years) after pT2-3
Fig. 2.2. Kaplan-Meier survival curve comparing pT2-3 primary(--) and progressive (-)
study groups.
For the N+ group, the curve has a similar trend as the total study population
and the pT2/3 group (p = 0.03). (Figure 2.3). There was no statistical
significant difference in disease specific survival for the pT4 group and the M+
Difference in prognosis between primary and progressive invasive bladder cancer
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group between patients with a progressive tumor and the study group (p =
0.28 and p = 0.49 respectively), but numbers are small for these subgroups.
Multivariable analysis (Table 2, Model I) shows a hazard ratio of 0.49 (95% CI
0.32 to 0.77) for the primary group versus the progressive tumor group. This
means that the risk for disease-specific death in the primary group is about half
(0.49) the risk in the progressive group at all times during follow-up. The
second model (II), including age and gender, shows that age and gender are no
independent predictors of survival in our study. Model III shows that the
pathological stage does not have any significant effect on the results.
Follow-up (years) after diagnosis N+
Fig. 2.3. Kaplan-Meier survival curve comparing N+ primary (--) and progressive (-) study
groups.
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However, as expected, the presence of nodal or distant metastasis significantly
increases disease-specific death risks with a hazard ratio of 2.07 (95% CI 1.27
to 3.40) and 6.77 (95% CI 3.52 to 13.04) respectively. Due to the small number
of patients in this study, interaction terms between study groups and stage
groups could not be studied.
Discussion
The current study shows a large difference in disease-specific survival between
primary and progressive muscle-invasive bladder cancer patients, favoring the
primary group. The disease-specific survival appears to be approximately twice
as high in the primary group at all times during follow up. The 3 and 5-year
survival rates are 67% and 55% respectively for patients with a primary
invasive tumor and 37% and 28% respectively for patients with a progressive
invasive tumor.
Table 2.2. Multivariate analysis of disease specific survival in muscle-invasive bladder
cancer
Hazard Ratio 95% CI
Model I
Study group
(Primary versus Progressive tumor)
0.49 0.32 – 0.77
Model II
Study group
(Primary versus Progressive tumor)
0.50 0.31 – 0.78
Gender
(Male versus Female)
0.78 0.48 – 1.29
Age 1.00 0.98 – 1.02
Model III
Study group
(Primary versus Progressive tumor)
0.52 0.33 – 0.82
Stage group
(pT4 versus pT2/3)
0.43 0.10 – 1.82
Stage group
(N+ versus pT2/3)
2.07 1.27 – 3.40
Stage group
(M+ versus pT2/3)
6.77 3.52 – 13.04
Difference in prognosis between primary and progressive invasive bladder cancer
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This trend in survival difference between the two study groups was observed
in the Nijmegen population as well as in the Rotterdam patients: in both
centers patients with progressive invasive tumors had a significantly worse
prognosis compared to patients with primary invasive tumors.
Although this was a retrospective study, with no standard treatment protocol
for primary and/or progressive invasive tumors, in both centers no difference
was madder regard to advised therapy in case of a primary invasive tumor or a
history of previous invasive disease. Moreover, treatment advises (radical
surgery in case of invasive nonmetastasized tumors, and chemotherapy in case
of metastasized tumours) were comparable in both academic centers and
constant over the years of the period of retrospective analysis. Therefore,
potential differences in treatment should have been equally distributed between
both study groups. This is illustrated by the observation that overall survival
results of primary invasive tumors are comparable between the two centers,
with literature, and the 3- and 5-year survival of invasive bladder cancer
according the Netherlands Cancer Registry (60% and 55%, respectively) [7].
Furthermore, the survival differences between the two study groups were
comparable between the two centers, which suggest that pooling these results
did not cause bias, but enabled us to draw a firmer conclusion.
The mechanism behind this observed difference is not so easily understood.
Since survival figures of the patients with primary invasive are comparable with
literature and the results of the Netherlands Cancer Registry, the explanation
for the significant differences between the two groups has to be found in the
worse survival of patients with progressive muscle-invasive bladder cancer.
One possible explanation could be that in high risk superficial bladder tumors
both therapy- sensitive and therapy-insensitive cells coexist. Intravesical
therapy may select resistant clones and more aggressive tumor cells may
continue to grow and progress to invasive bladder cancer.
Another interesting possible explanation could be a recent finding published by
El-Abbady et al. [8]. They compared 16 patients with progressive invasive
tumors with 20 patients who were diagnosed with primary invasive tumors, all
undergoing cystectomy. On meticulous histopathological examination they
found that patients who underwent previous transurethral resections had
significantly more local spread of malignant cells into the bladder muscle as
compared to patients with primary invasive tumors. Since they could
demonstrate that intravesical pressure reaches pressures as high as 80 cm
water, they suggested some malignant cells penetrate through the denuded
urothelium during resection as a result of high intravesical pressures. Similarly,
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random biopsies during resection of superficial tumors might cause tumor cell
implantation at the site of the damaged mucosa, and influence the prognosis.
However, two large series clearly demonstrated that the risk of recurrence and
the risk of progression is almost the same comparing a “biopsy policy” and a
“no biopsy policy” [9,10]. Moreover, as was argued above, since both groups
were stage matched, this finding potentially could explain progression of high
risk superficial disease, but not the difference between the pathologically
matched groups of the current study.
To our best of knowledge, the current study is the first published on invasive
bladder cancer that demonstrates a statistically significant survival advantage
for patients without a history of superficial bladder cancer. The findings of this
study emphasize one of the most challenging questions in the treatment of
patients with superficial bladder cancer: the choice between conservative and
radical therapy. The ideal situation would be if we could recognize those
tumors with aggressive potential with prognostic factors. However, although
numerous studies have been undertaken to identify better prognostic factors of
progression to muscle invasive disease, a dear consensus has not been reached
[11]. The most reliable factors affecting tumor progression remain high grade
(G3), stage pTl and pTl subclassification, concurrent CIS, high recurrence rate,
no complete remission with BCG immunotherapy and p53 expression
[2,12,13].
The current conservative approach for a patient with a high risk superficial
tumor (e.g. pT1G3 with CIS) remains an adequate TUR followed by
intravesical BCG therapy. Three recent reports with approximately 100
patients each and a follow-up of more than 10 years clearly concluded that,
especially as primary treatment, complete resection and intravesical BCG in
high risk disease is the treatment of choice [14-16]. The recent meta-analysis of
Sylvester et al. even suggested that maintenance intravesical BCG significantly
reduces or delays the risk of progression, and therefore is the drug of choice in
intermediate and high risk patients after resection [17]. However, the
observation that progressive patients do bad, can also be concluded from this
meta-analysis. Looking at the number of deaths due to bladder cancer and at
the progression data of these same trials the chance of death due to bladder
cancer in case of progression is around 64% with a median follow-up of 2.5
years, irrespective of BCG treatment. Although these numbers do not
completely match, the results appear “amazingly similar” to the 67% 3-year risk
of bladder cancer death rate in our report for progressive patients (personal
communication with Sylvester RJ). This again emphasizes the bad prognosis of
these progressive patients.
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This risk of conservative therapy in high risk patients, together with the
excellent survival data from early cystectomy in high risk superficial bladder
cancer indicates that radical surgery remains a realistic treatment option in
these patients [18].
Conclusion
The time window for conservative therapy in high risk superficial bladder
cancer is small. On the one hand very good long term results with prevention
or delay of progression can be achieved with maintenance intravesical BCG,
while on the other hand, as soon as progression has occurred, the change of
dying due to bladder cancer significantly increases. Therefore, in high risk
patients with recurrent or persisting tumor at initial evaluation, radical surgery
should be seriously considered.
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Abstract
Objective: The aim of the study was to confirm the predictive value of cell cycle
regulatory proteins p53 and p27kip1, and the cell adhesion complex protein α-
catenin, for progression in patients with superficial bladder carcinoma.
Methods: Forty-one patients with progression after primary superficial bladder
carcinoma were individually matched to patients with nonprogressive
superficial bladder carcinoma. Matching was done for sex, age, tumor stage and
grade, concomitant carcinoma in situ (CIS), and duration of follow-up.
Immunohistochemical analysis of p53, p27kip1 and α-catenin was performed on
each primary bladder tumor. Analysis for the p53 mutation was done on 41
bladder tumor samples. Conditional logistic regression analysis was used to
establish the prognostic value of immunohistochemical p53, p27kip1, and α-
catenin status.
Results: The independent odds ratios for progression were 0.3 (95% CI: 0.1-1.2)
for high-risk p27kip1, 3.4 (95% CI: 0.8-15.2) for high-risk p53 and 2.5 (95% CI:
0.6-10.3) for high-risk α-catenin. Combinations of different markers had no
synergistic effects. Two p53 mutations were found in 21 DNA samples
analyzed from nonprogressive tumors (9.5%); 8 out of 20 samples (40%) from
progressive tumors showed a p53 mutation. The probability of high-risk p53
immunostaining was 5-fold increased in case of mutations in p53. The
estimated positive predictive value of high-risk p53 and/or high-riskα-catenin
was about 23%.
Conclusions: We confirm that high-risk p53, p53 mutation and α-catenin
immunohistochemistry do have an additional prognostic value in primary
bladder carcinoma. However, the clinical value of the investigated parameters
remains limited.
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Introduction
In Europe and the United States, each year, approximately 20 new cases per
100,000 persons are diagnosed with bladder cancer, resulting in 5 per 100,000
persons dying from this disease annually [1].The majority of these cancers are
superficial urothelial cell carcinomas (UCC). These lesions appear as papillary
tumors limited to the mucosa (Ta) or invading the lamina propria without
involving the muscularis propria (T1) or as flat carcinoma in situ (CIS) with
diffuse malignant cells confined to the mucosa. The likelihood that superficial
bladder cancer will recur is about 70% in 5 yr with a peak incidence in the first
year after initial treatment. As many as 30% of these recurrent tumors present
with a higher histologic grade and about 10% progress to muscle-invasive
tumor, leading to death if not treated [2].
The clinical course of superficial bladder cancer is rather unpredictable.
Traditional prognostic factors to predict clinical outcome of bladder carcinoma
are tumor size, stage and grade, concomitant CIS, tumor recurrence rate and
multiplicity. However, it is generally accepted that these prognostic factors are
not accurate enough to define the risk of tumor recurrence and to predict
disease progression for the individual patient [3]. With a better understanding
of the cell cycle and cell to cell and cell to extracellular matrix interactions,
progress is being made to identify and characterize other potential prognostic
markers for UCC of the bladder. The cell cycle regulatory proteins p53 and
p27Kip1, and the cell adhesion complex protein α-catenin are considered
potentially useful prognostic markers [4,5,6].
The present study aimed to confirm the predictive value p53, p27kip1 and α-
catenin in patients with progression from superficial to muscle-invasive bladder
cancer.
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Material and methods
Patients
Forty-one patients with superficial UCC of the bladder, who progressed to
muscle-invasive or disseminated disease (or both) 6 mo to 10 yr following the
initial diagnosis, were selected. For each patient with progressive disease a
control patient with nonprogressive superficial bladder cancer was selected.
Matching was done for sex, age, primary tumor stage and grade, the presence
of CIS and duration of follow-up (ie, patients without disease progression had
to had a longer follow-up than their match). In total, 74 men and 8 women
were included in this study. Six patients with progressive disease had
concomitant CIS in addition to their primary tumor. These six patients were
matched with the same number of patients with a nonprogressive tumor with
concomitant CIS. The primary tumor and concomitant CIS of the progressive
and nonprogressive groups were analyzed separately.
Tumor specimens
Table 3.1. Stage and grade of the primary tumors of patients with progressive and non-
progressive bladder carcinoma
StageGrade
pTa pT1 CIS
(primary,
n=41)
CIS
(concomitant,
n=6)
I 2
II 12 8
III 3 10 6 6
The archival paraffin-embedded primary tumor specimens were derived from
retrospectively selected patients, who were treated in the period between 1980
and 2000 for bladder cancer at our institution. In total, 94 paraffin-embedded
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primary bladder tumor samples from 82 patients were analyzed immunohisto-
chemically for p27Kip1, p53 and α-catenin expression (2 x 41 tumour + 2 x 6
CIS). All primary tumors were staged according to the TNM classification [7]
and graded according to the World Health Organization classification system
[8]. Table 3.1 shows the stage and grade distribution are shown of the primary
tumours of the patients with progressive bladder carcinoma. Because the
control group is matched to the group of patients with progressive disease,
Table 3.1 also represents the primary tumors of the patients with
nonprogressive tumors.
Immunohistochemistry (IHC) and scoring
We performed p27Kip1, p53 andα-catenin, immunohistochemical staining using
serial sections from the same paraffin-embedded blocks. Staining protocols
for p27Kip1 (monoclonal antibody to p27Kip1; Transduction Laboratories,
Lexington, KY), p53 (monoclonal antibody to p53 [clone DO7]; Neomarkers,
Fremont, CA) and α-catenin (monoclonal antibody to α-catenin; Transduction
Laboratories, Lexington, KY) have been described elsewhere [9,10]. All
markers where placed in one of two categories, high or low risk, by two
investigators (J.L.J.V. and J.A.S.) who where blinded to clinical outcome.
Table 3.2. Immunohistochemical p27Kip1, p53 and α-catenin expression pattern in
primary superficial bladder carcinoma of progressive and non-progressive tumors
Marker Patient group Low-risk High-risk Non-evaluable
Progressive 22 20 5p27Kip1
Nonprogressive 17 28 2
Progressive 21 23 3p53
Nonprogressive 30 16 1
Progressive 17 22 8α-catenin
Nonprogressive 28 16 3
Among the 47 patients in each progressive and nonprogressive group, in 6 patients with
and 6 patients without progression, both the primary tumor as well as the concomitant
CIS component were analyzed separately.
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Nuclear immunoreactivity was considered high risk when < 25% of the tumor
cell nuclei for p27Kip1 or ≥10% or more of the tumor cell nuclei for p53
showed clear staining. The scoring system used is a dichotomous variant of
earlier described scoring systems [11]. The distribution of α-catenin staining
was classified by the observers according to its localization in the cell.
Normal bladder epithelium present in the tumor sections was used as internal
positive control. Tumors were classified as normal if discrete staining was
present at cell-cell contacts only. The presence of an aberrant (apical or
cytoplasmic location of staining) or negative staining in > 10% of the
malignant cells was defined as high risk [12].
Extraction of DNA for p53 mutation analysis was performed, as described
previously, with the use of DEXPAT (TaKaRa Biomedical Europe S.A.,
Gennevilliers, France) [13]. Exons 5 through 8 of the p53 gene, in which 90%
of all mutations are found, were analyzed for point mutations by Polymerase
Chain Reaction (PCR), single-strand conformation polymorphism (SSCP), and,
in case of a band shift, subsequent cycle sequencing. Only sequence differences
that were reproducible in both orientations were scored as mutations.
Statistical analysis
Differences in the distributions of the molecular markers between the patients
with and the patients without progression were evaluated for statistical
significance with the McNemar test for paired proportions. Statistical
significance was assumed at p < 0.05. In these univariable analyses, the ratio of
the number of discordant pairs (odds ratio (OR) reflects the prognostic value
of each molecular marker (p27Kip1, p53 and α-catenin). To evaluate the
independent prognostic value of these molecular markers, conditional logistic
regression analysis for matched pairs was performed. The correlation between
p53 status by immunohistochemistry (IHC) and p53 status by mutation
analysis was quantified with an OR. The Statistical Package for Social Sciences
(SPSS, version 9.0) computer software was used for data documentation and
univariable analysis. The PHREG procedure in the Statistical Analysis System
(SAS, version 6.12) software was used for conditional logistic regression
analyses.
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Results
Table 3.2 presents the expression patterns of p27Kip1, p53 and α-catenin. In 7
cases the p27 status could not be determined due to technical reasons. The
same occurred in 4 p53 samples and 11 α-catenin samples.
Table 3.3. Immunohistochemical p27Kip1, p53 and α-catenin expression results in
matched pairs of one progressive and one nonprogressive tumor
Nonprogressive tumorsMarker Progressive
Tumors Low-
risk
High-
risk
Total
Univariable
OR
(95%CI)
Multivariabl
e
OR
(95%CI)
Low-risk 8 12 20
High-risk 6 14 20
p27Kip1
Total 14 26 40
0.5
(0.2-1.4)
0.3
(0.1-1.2)
Low-risk 18 3 21
High-risk 11 11 22
p53
Total 29 14 43
3.7
(1.0-13.5)
3.4
(0.8-15.2)
Low-risk 12 4 16
High-risk 11 11 22
Α-
catenin
Total 23 15 38
2.8
(0.9-8.8)
2.5
(0.6-10.3)
The results of conditional logistic regression analysis for matched pairs are also shown.
OR = odds ratio; CI = confidence interval.
Table 3.3 shows the immunohistochemical results of p27Kip1, p53 and α-catenin
obtained in the matched pairs of one progressive and one nonprogressive
tumour. The ORs for the different markers are shown. Due to a number of
nonevaluable samples not all 47 pairs could be analyzed.
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Conditional logistic regression for matched pairs was performed to calculate
the independent prognostic value of the molecular markers. The resulting ORs
(Table 3.3) are 0.3, 3.4 and 2.5 (all not significant) for p27Kip1, p53 and α-
catenin respectively.
Only 41 samples of extracted DNA could be used for amplification, SSCP, and
subsequent automated sequencing of exons 5 through 8 of the tumour
suppressor gene p53. Two p53 mutations were found in the 21 DNA samples
analyzed from nonprogressive tumors (9.5%); 8 out of 20 samples (40%) from
progressive tumors showed a p53 mutation. Although only a small number of
samples could be analyzed for p53 mutation analysis a comparison with p53
IHC was made. The sensitivity of IHC, defined as percentage of IHC high-risk
tumors among tumors with identified mutation, was 50% (5 out of 10). The
specificity of IHC, defined as percentage of IHC low-risk tumors among
tumors without a p53 mutation, was 84% (26 out of 31). 16% (5 out of 31) of
the tumors without a p53 mutation showed p53 overexpression. An OR of 5.2
(95%CI: 0.8-32.4) was calculated, which means that the probability of high risk
immunostaining is 5-fold increased in the case of mutations in p53.
Discussion
Progression to muscle-invasive disease occurs in about 10% of patients with
superficial UCC. The ultimate challenge is to identify these patients before
progression occurs, especially because patients with muscle-invasive bladder
cancer and a history of superficial bladder cancer have a worse prognosis than
patients with primary muscle-invasive disease [14]. Unfortunately, the
conventional prognostic factors are highly inaccurate to predict true biological
behaviour in individual patients [3]. New prognostic markers are needed to
individualize the treatment of patients with high risk superficial bladder cancer.
p27Kip1
The cyclin-dependent kinase (CDK) inhibitor p27Kip1 regulates the G1 to S
phase transition of the cell cycle by binding to and inhibiting several CDK
complexes in normal cells [15]. Increased levels of p27Kip1 serve as a barrier for
progression to S phase and signal exit from the cell cycle. Recent studies have
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suggested that decreasing protein levels of p27Kip1 may be associated with
transformation of bladder tumor cells into more aggressive cancers with early
recurrence and shortened survival [16,17]. The results for p27Kip1 found in our
study contradict the literature. We found that high-risk p27Kip1 expression (low
protein levels of p27Kip1) has an OR of 0.3 and seems therefore to have a
protective function in progression. An explanation for this discrepancy might
be found in fixation techniques of the archival material. It is known that large
specimens, which are slowly fixed over several hours, retain strong p27Kip1
expression only in the outer aspect of the samples, which are promptly fixed.
This could cause an under expression of p27Kip1 in the central part of the
specimen.
p53
p53 acts as a cell cycle control protein at the level of G1 to S phase transition.
DNA damage can be detected by p53, resulting in an increased level of p53.
High p53 protein levels block cells in the G1 phase. DNA damage can be
eliminated either by DNA repair or by initiation of apoptosis. This mechanism
decreases the chance of mutant cell development and cancer formation [18].
In general, p53 over expression is much more common in muscle invasive
disease than in superficial bladder cancer. The usefulness of p53 in stage Ta
disease is questionable [19]. In stage T1 bladder cancer over expression of p53
has been shown to be an independent prognostic marker for disease
progression [20]. We found that high-risk p53 (positive staining > 10%) had an
OR for progression of 3.4.
p53 Mutation
Mutations in and loss of the p53 gene are the most common genetic defects in
human malignant tumors [21]. Alterations of the p53 gene result in loss of
function. Mutated p53 undergoes conformational changes, resulting in a
prolonged half-life and subsequent accumulation of the protein. Because of the
minute amounts and rapid turnover of p53 in the healthy situation, it has been
suggested that overexpression of immune-detectable p53 is synonymous with
mutation [22]. Direct molecular analysis for the presence of mutations might
be a more valuable tool than IHC of p53. Although there is a good
concordance between p53 over expression and mutation of the p53 gene in
Chapter 3
41
some studies [23,24], several other studies have shown a considerable
discrepancy (20-30%) between molecular genetic alteration in p53 and over
expression of the protein [25,26]. In our study the probability of high-risk
immunostaining increased 5-fold in the case of a p53 mutation, indicating a
fairly good but imperfect concordance. Although the number of analyzed
tumors in this study is small, the results confirm that p53 mutations have a
prognostic value.
α-Catenin
Cadherins mediate intercellular adhesion in epithelial tissues. Loss of cell-cell
adhesion, allow malignant cells to escape from their primary lesion, invade
surrounding tissues and finally metastasize [6,27]. Cadherins are linked to the
cytoskeleton through catenins. Proper linkage to the cytoskeleton is
indispensable for E-cadherin function. Shimazui et al. showed that reduced
expression α-catenin in bladder tumors correlates with poor survival [28]. An
OR of 2.5 for progression was found for high-riskα-catenin in our study.
In this study we chose to establish the independent prognostic value of p53,
p27Kip1 and α-catenin for progression with a case-control design. This choice
was based on the desire to obtain an optimal control for other prognostic
factors while only a small series of patients with progressive disease was
available. The independent ORs for high-risk p27Kip1, high-risk p53 and high-
riskα-catenin expression calculated in these paired groups were 0.3, 3.4 and 2.5,
respectively (Table 3.3). The similarity between the results obtained with the
univariable and the multivariable analyses suggests that the prognostic value of
the markers is independent of each other. Inclusion of interaction terms in the
multivariable model did not change the results. This suggests that
combinations of different markers do not have synergistic effects. Probably
due to the small number patients tested in this study the ORs for progression
of the markers are not statistically significant unlike the previous reports
released by other groups.
Because of our paired design, half of the group progressed from superficial
tumors to muscle-invasive and/or disseminated disease. The other half, the
control group, did not progress; these patients only had superficial recurrences
after their primary superficial bladder tumor.
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Due to the design of our study we artificially increased the prevalence of
progression to 50%. This means that it is not possible anymore to directly
translate the results to the risk of progression for patients with or without a
high-risk expression of p53 and/orα-catenin in the primary tumor.
Table 3.4. The results of p53 and α-catenin immunohistochemistry in the progressive
and non-progressive group of patients.
Our study population Hypothetical high risk group
Non-
progressive
Progressive Total Non-
progressive
Progressive Tot
al
Low-
risk
p53
and
Low-
risk α-
catenin
20 12 32 180 12 192
High-
risk
p53
and/
or
high
risk α-
catenin
24 29 53 216 29 245
Total 44 41 85 396 41 437
This prevalence would correspond better with the cumulative risk of
progression among a high-risk superficial bladder cancer group. Among this
hypothetical high-risk population, the positive predictive value of high-risk p53
and/or high-risk α-catenin immunostaining can be estimated to be 12%
(29/245). This would mean that only one in eight to nine patients with the
high-risk phenotype would develop progressive disease. The negative
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predictive value can be estimated to be 94% (180/192). This means that only
about 1 in every 17 patients without the high-risk phenotype would develop
progressive disease. These results would not be very different if we define
aberrant p53 AND aberrantα-catenin staining as high-risk.
The prevalence of progression for the studied group was estimated using a
scoring system [29]. The most important factors for progression (stage, grade,
multiplicity and CIS) were used to categorize patients in low-, intermediate-, or
high risk groups. The observed risk for progressive disease for these groups
was 4, 12 and 21%, respectively. The mean risk for progression was 12% for all
the patients in this study. These results were confirmed using the scoring
system of the European Organization for Research and treatment of Cancer
(EORTC) [30]. With this method the risk for progression was determined for
each patient studied using the same factors for progression. A mean risk for
progression of 11% was calculated for our studied group using this system.
In an attempt to translate the results to the clinic, we arbitrarily changed the
prevalence of progression from 50% to 12% by multiplying all results among
the controls (patients without progression) by a factor 9 (Table 3.4).
As stated before, we included 6 matched pairs with concomitant CIS.
Consequently, the samples with CIS and with the other primary tumor were
assumed to be independent which may not be a valid assumption. In order to
avoid any bias of the results, we repeated the analysis with only one of both
tumours of these 6 matched pairs. The results did not change dramatically. The
multivariate odds ratios were 0.2, 3.1 and 3.9, for p53, p27Kip1 and α-catenin,
respectively. This suggests that, although high-risk p53 and α-catenin IHC do
have an additional prognostic value above the clinical parameters like grade,
stage and presence of CIS, the clinical value of these parameters remains
limited.
Another concern in this study is that a number of tumors were not suitable for
reliable scoring of p53 (4 of 94), p27Kip1 (7 of 94) and the α-catenin (11 of 94).
This can be explained by tissue fixation problems and quality of biopsy
specimens. Also, only a small number of tumors could be analyzed with p53
mutation analysis. This was partly due to the low quality of extracted DNA.
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DNA preservation is dependent on fixation time and type. Formalin fixation
damages DNA, limiting the size of the template that can be successfully
amplified. The oldest tumor samples were dissected in 1980 and methods of
fixation have been improved since then. Standardization of fixation is
recommended together with extra care for good quality biopsies and resected
tumor samples, to improve immunohistochemical and mutation analysis results.
Conclusion
We confirm that high-risk p53 and α-catenin IHC do have an additional
prognostic value to traditional parameters like tumor stage and grade and
concomitant CIS in primary bladder carcinoma. The value in every day clinical
practice remains limited.
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Abstract
Objectives: A retrospective study was performed to determine the prognostic
value of perineural invasion (PNI) and angiolymphatic invasion (ALI) in
patients with invasive bladder carcinoma (pT2-3) without signs of metastases
(N0, M0) who underwent a radical cystectomy and did not receive (neo)
adjuvant treatment.
Materials and methods: The pathological slides of 44 patients were reviewed.
Comparisons were made between four groups: PNI alone, PNI with ALI, ALI
alone and a control group (no PNI or ALI). To verify true ALI,
immunohistochemical staining was performed on slides with an endothelial
marker (antibodies for Factor VIII-related antigen). Statistical significance in
survival rate was calculated for pathological stage, tumor grade, ALI and PNI.
Results: The mean patient age was 63 years (range 41 to 78). The mean follow-
up period was 39 months (range 4 to 142). PNI was predominantly found in
stage pT3b disease (12 of 15 [80%] cases). The overall 3-year disease-free
survival was 62%. The differences in survival for tumor stage and grade were
not statistically significant (p = 0.7 and p = 0.3, respectively). Patients with
PNI had a 3-year survival of 51%. Without PNI, a 3-year survival of 69% was
seen. This difference was also not statistically significant (p = 0.2). The 15
patients without ALI showed a borderline better 3-year survival compared to
the patients with ALI (85% versus 49%, p = 0.05). Only in one case ALI was
detected with the endothelial marker whereas it was missed on routine stained
slides. In two cases ALI seen on routine stained sections could not be
confirmed with immunohistochemistry.
Conclusions: PNI does not appear to be independent of pT3 and is, therefore,
not an independent prognostic factor for survival. The prognostic value of ALI
is borderline significant for disease-free survival rate.
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Introduction
Association between increasing depth of bladder wall penetration by tumor
with impaired prognosis and development of metastases was noted by
Geraghty in 1922 [1]. It was not until 1946, that depth of tumor invasion was
used by Jewett and Strong for clinical staging [2]. This staging was adopted by
the UICC in 1978 and is still used in the present TNM classification [3]. One
of the most important prognostic factors is the extent of the tumor. PNI has
been correlated with a worse prognosis in cancers of the esophagus, stomach,
gallbladder, pancreas, rectum and skin. Close association with ALI and worse
prognosis has been noted in all these studies [4-9]. PNI with or without ALI
and ALI alone in transitional cell carcinoma (TCC) of the bladder are
associated with a higher incidence of nodal and extranodal metastases and
death [10]. A retrospective study was performed to determine the prognostic
value of PNI and ALI in patients with invasive bladder carcinoma without
signs of metastases and without neoadjuvant treatment, undergoing a radical
cystectomy.
Materials and methods
We performed a retrospective study of 44 patients with invasive TCC of the
bladder who underwent radical cystectomy and bilateral pelvic lymph node
dissection. All patients were operated between July 1985 and November 1998.
Patients with invasive TCC stage pT2 or pT3 were included. Patients who had
regional nodal metastases and/or distant metastases at time of cystectomy or in
final pathology results were excluded. Patients who received (neo) adjuvant
therapy were also excluded.
Transurethral resection and cystectomy pathology specimens were reviewed by
one of the authors (CHvdK) who was unaware of the clinical outcome. The
1997 tumor, lymph nodes, metastasis (TNM) system was used for pathological
staging. The tissue samples from the slides selected had been previously fixed
in buffered formalin, paraffin-embedded and stained with hematoxylin & eosin
(H&E). Meticulous investigation took place to see if tumor cells could be
observed within the perineurium as sign of PNI. The presence or absence of
small vessel invasion was sought carefully. Only when tumor cells were present
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within the vascular and/or lymphatic lumen ALI was confirmed. No difference
was made between vascular and lymphatic invasion. To verify true ALI
immunohistochemical staining was performed on the slides with antibodies for
Factor VIII-related antigen as endothelial marker. The endothelial marker was
used in those slides that contained the most ALI. If there was no ALI found
on first examination, the endothelial marker was used in those slides containing
most tumor. ALI was accepted for statistical analysis when it was found on
H&E and confirmed with the endothelial marker.
Survival rates were calculated using the Kaplan-Meier method from the date of
radical cystectomy to the date of recurrence, death of other cause or last
known follow-up. Univariate analysis was performed in which each potential
predictor of outcome was examined for statistical significance using the log-
rank test (Table 4.1). The variables evaluated were pathological stage, tumor
grade, ALI and PNI. The impact of ALI on survival was assessed using Cox
proportional hazard regression and multivariate analysis for ALI, PNI, grade
and stage.
Table 4.1. Summary of statistical analysis
Variable p Values log rank
Grade 0.3
Stage 0.7
PNI 0.2
ALI 0.05
Results
The population of 44 patients with invasive TCC included 29 men and 15
women. The mean age was 63 years (range 41 to 78). The mean follow-up
period was 39 months (range 4 to 142). A high-grade tumor was seen in 41
patients and 3 patients had a low-grade tumor. According to the TNM (1997)
classification, 12 patients had a pT2, 15 patients a pT3a and 17 patients a pT3b
tumor. In 38 patients, the invasive tumor was diagnosed as primary. Only 6
The prognostic value of PNI and ALI in non-metastasised invasive bladder cancer
54
patients had a history of superficial bladder tumor. Tumor recurrence was seen
in 14 (32%) patients. Local recurrence occurred in 4, retroperitoneal lymph
node metastases in 2 and bone metastases in 3 patients. Liver, lung, omentum,
intestinal and abdominal wall metastases were seen in 1 patient each. Of these
14 recurrences, 3 patients had a pT2, 5 a pT3a and 6 a pT3b tumor. The
recurrences developed at the mean duration of 14 months (range 5 to 27).
In 15 (34%) patients PNI was detected (Table 4.2). ALI was found in 12(80%)
of these 15 patients. In 29 patients, ALI was found; in 17 of these cases
without PNI. In the 14 patients with recurrent tumor, PNI was detected in 7
(50%) patients, which were all positive for ALI. All 4 patients with low grade
TCC were negative for PNI.
Table 4.2. Perineural invasion (PNI) and angiolymphatic invasion (ALI) compared
with tumor stage (T)
Total PNI PNI+, ALI+ ALI ALI-, PNI-
pT2 12 (27%) 1 (7%) 1 (8%) 5 (17%) 7 (58%)
pT3a 15 (34%) 2 (13%) 1 (8%) 11 (38%) 3 (25%)
pT3b 17 (39%) 12 (80%) 10 (84%) 13 (45%) 2 (17%)
44 (100%) 15 (34%) 12 (27%) 29 (66%) 12 (27%)
The 12 patients without ALI or PNI were studied as control group. Two of
these patients had a low-grade tumor, the remaining 10 patients a high-grade
tumor. A recurrent tumor was seen in 2 patients. One had a pT2 and the other
a pT3a tumor. The overall 3-year survival was 62%. The 3-year survival for
pT2 was 73%, for pT3a 57% and for pT3b 60%. (p = 0.7). Also, the difference
in 3 year survival for tumor grade, 100% in low grade and 60% in high grade
were not statistical significant (p = 0.3).
Patients with PNI had a 3-year survival of 51%. Without PNI, a 3-year survival
of 69% was seen. This difference was also not statistical significant (p = 0.2).
The 15 patients without ALI showed a borderline better 3-year survival
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compared to the patients with ALI (85 versus 49%, p = 0.05). The Kaplan-
Meier curves for survival with and without ALI are shown in Figure 4.1.
Compared with patients without ALI, patients with ALI had a risk ratio (RR)
of 3.6 (95% CI, 0.8 to 16.0) for recurrent disease leading all to death.
Fig. 4.1. Kaplan-Meier curves for patients with (•) and without (O) ALI
Multivariate analysis for ALT, PNT, grade and stage showed a RR for patients
with ALI of 3.3 (95% CI, 0.7 to 15.6) for recurrent disease.
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Discussion
The aim of this study was to evaluate the significance of the histopathological
features as prognostic factors in patients with invasive TCC without signs of
metastases who underwent a radical cystectomy and had no adjuvant treatment.
Identification of prognostic factors is important to predict the clinical outcome.
Patients who are at higher risk for tumor progression can be identified, so
optimal adjuvant therapy can be tailored to the patient [11].
The relation between depth of bladder wall invasion and impaired prognosis
and development of metastases is reported in many studies. Bassi et al. reported
in 1999 on the predictive variables in a retrospective study of 369 patients with
bladder cancer. All stages of bladder cancer were included in this study. He
noticed that survival was directly related to the pathological stage. As tumor
stage progressed from pTa through pT4 survival significantly decreased (p
<0.0000). The estimated 3-year survival was 70% for pT2, 60% for pT3a and
50% for pT3b. The authors concluded that tumor stage together with nodal
involvement were the only independent predictors of survival in a multivariate
analysis [12]. The prognostic value of the pathological stage was not significant
(p = 0.7) in our study. The 3-year survival rates for our patients were
comparable with those of Bassi et al. However, we only included patients with
pT2 and pT3 tumors and studied a smaller group of patients. These facts
explain the lack of significant difference in survival between these stages in our
study.
There are many reports about tumor grade having a significant predictive
outcome after radical cystectomy [13-16]. Not all authors reported differences
in survival between tumor grades to be statistically significant [17]. A possible
explanation is given by Ooms et al. They noticed a high inter- and intra-
observer variability in the grading of bladder tumors by pathologists [18]. In
our study, only patients with invasive bladder tumors were included. Invasive
tumors are almost always high-grade tumors. This is probably the explanation
why significance could not be demonstrated for tumor grade.
The prognostic value of PNI for invasive TCC of the bladder was first
described by Naglia et al. They reviewed in a retrospective study 27 patients
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with TCC treated with radical cystectomy. They noticed that the presence of
PNI in radical cystectomy specimens was associated with a higher incidence of
nodal and extranodal metastatic disease and death. PNI was predominantly
found in stage pT3b disease (14 of 20 [70%] cases). For this reason, the
authors suggested that PNI alone is not an independent prognostic factor of
outcome [10]. Univariate analysis in the study of Bassi et al. revealed
significantly better 5-year survival for the 347 (56%) patients without PNI
compared to the 22 (44%) patients with PNI (p = 0.0007). So, PNI appeared
to be a predictor of survival in this study. In both studies all tumor stages were
included, in contrast with our study as we included only patients with pT2-3
tumors.
We could not demonstrate a significant difference in survival for PNI (p = 0.2).
Exactly like Naglia et al., we found a predominance of pT3b disease in patients
with PNI (12 of 15 [80%] cases). This can also explain the lack of independent
prognostic value of PNI, since most nerves are located in the deeper layer of
the bladder wall and, therefore, an association between deep invasion of
tumour and PNI seems obvious, causing disappearance of the prognostic value
of PNI in a multivariate analysis.
The prognostic importance of vascular involvement in patients with bladder
carcinoma was already recognized in 1948 by McDonald and Thompson [19].
In 1964, Jewett et al. suggested that tumors invading lymphatic vessels could
give metastases, which is associated with poor prognosis. Since then, only few
studies made a dear association between ALI and decrease in survival
[10,12,20,21].
The reason for inconsistencies regarding ALI and prognosis is that a variety of
tissue artefacts can make recognition of ALI by tumour cells extremely difficult.
As vessels become progressively smaller, identifying them becomes
increasingly difficult for the pathologist. Some times, artificial spaces produced
by tissue tears or shrinkage artefacts caused by fixation cannot be differentiated
from blood vessel or lymphatic invasion. Great variations in the results from
one observer to the next in diagnosing lymphatic involvement of malignant
cells are reported [22]. Therefore, verification of ALI using an
immunohistochemical endothelial marker is, according to Ordóñez et al. very
useful [23]. There is an agreement that endothelial cells of blood and lymphatic
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vessels are positive for Factor VIII-related antigen (FVIIIR:Ag) [24,25]. We
used antibodies for FVIIIR:Ag as endothelial marker in all cases to verify ALI.
Only in one case ALI was seen with immunohistochemistry whereas it was not
seen on routine H&E stained sections. On the other hand, in two cases ALI
was not seen with immunohistochemistry whereas it was clearly seen on
routine H&E staining. In all the other 25 cases ALI was clearly observable in
the H&E stained slides. Therefore, in our hands, the use of this endothelial
marker was of little additional value to verify vascular or lymphatic invasion.
Heney et al. reviewed pathological slides of 82 patients who underwent radical
cystectomy for invasive bladder carcinoma. The histologic material
demonstrated ALI in 16 of 23 patients (70%) with and 30 of 59 patients (51%)
without nodal metastases. The presence of ALI conferred a much higher
likelihood of positive lymph nodes (16 of 46 [35%]) than when no ALI could
be identified (7 of 36 [19%]). The crude 3-year survival for patients with no
nodal metastases in this study was 43% with and 59% without ALI [20].
Bassi et al. [12] reported a significant relation between survival and ALI in
patients with invasive bladder tumors. He estimated a 5-year survival rate for
the presence of vascular invasion of 29% versus 56% without vascular invasion
(p = 0.0011). For the presence of lymphatic invasion, the estimated 5-year
survival rate was 39 versus 61% without lymphatic invasion (p <0.0000) in
their report. Unfortunately, these data included all tumor stages including
nodal involvement. Moreover, in a multivariate analysis both vascular and
lymphatic invasion lost their independent prognostic value. In our study, the
prognostic value of ALI was borderline significant (p = 0.05). The patients
with ALI had a 3-year survival rate of 49% versus 85% without ALI.
The RR for patients with ALI to develop recurrent disease in our study was 3.6.
After correcting the RR in a multivariate analysis for PNI, grade and stage the
RR was 3.3. The small difference between these RR’s suggests an independent
prognostic value of ALI. The wide CI is due to the small group of patients.
Invasive bladder carcinoma is often a systemic disease at the time of initial
presentation. Up to 50% of these patients have occult metastases. The rapidity
with which occult metastases make themselves evident is impressive. Over
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three-quarters are detectable within the first post cystectomy year. Metastases
are most commonly seen in liver, lungs and bones. Death ensued usually
within several months after the diagnosis of metastases [26-29]. ALI is an
unfavourable prognostic factor and in our view a warning signal that silent
metastases are present. Silent metastases are micrometastases which are
probably best treated when the volume is minimal. Treatment with M-VAC is
effective in TCC with response rates up to 70% [30]. To improve the survival
rate for patients with pT2-3N0M0 TCC with ALI, early adjuvant
chemotherapy with M-VAC should be considered. This needs to be evaluated
in clinical trials.
Conclusions
In conclusion, PNI is associated with pT3 and therefore is not an independent
prognostic factor of outcome. ALI seems to be a predictor of disease-free
survival rate. In our hands, immunohistochemistry was not very useful in
verifying ALI.
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Abstract
Objectives: The objective of the study was to compare continence rates and
urodynamic parameters among patients who had undergone orthotopic
bladder substitution with sigmoid or ileal segments.
Methods: Continent urinary reservoirs were constructed in 112 patients. Fifty
patients received a sigmoid neobladder (SN) and 62 patients an ileal
neobladder (IN). Thirty-four patients with a SN (mean age 64.4 years), and 20
with an IN (mean age 57.8 years) agreed to postoperative urodynamic
evaluation at a median time after surgery of 18 and 37 months, respectively.
Continence and urodynamic parameters were compared in both groups.
Results: The average reservoir capacity of the SN (296 ml) was lower than the
IN (546 ml). The majority of patients voided by the Valsalva maneuver and
achieved good peak flow rates [SN group 16.6 (range 7 to 32) ml/sec, IN
group 25.5 (range 5 to 35) ml/sec]. Of the patients with a SN 26 (76%) and
with an IN 15 (75%) emptied to near completion with a post-void residual
(PVR) of less than 100 ml. Daytime continence was achieved in 90% of IN
patients and 85% of SN patients. Only 9% of patients with a SN and 60% of
patients with an IN were continent at night.
Conclusion: A neobladder constructed from detubularized ileum or sigmoid
achieves adequate capacity with a satisfactory daytime continence rate.
Nighttime incontinence in patients with IN can be at least partly explained by
periods of high pressure due to neobladder contractions in combination with a
relaxed sphincter during sleep. The low nighttime continence rate of the SN is
probably related to its small functional capacity.
Introduction
Many different methods of bladder substitution have been developed in the
attempt to achieve the goal of a neobladder that functions as well as a normal
bladder. The ideal neobladder substitute should have adequate capacity, store
urine at low pressure, preserve continence, evacuate via the urethra with
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minimal residual urine, preserve the upper urinary tract and renal function, and
cause no or minimal metabolic disturbance. Various segments of small and
large bowel have been used for neobladder construction.
The use of sigmoid colon for the creation of a continent voiding pouch was
initially popularized in the United States at the University of Minnesota. The
Minnesota group developed a partially detubularized U-shaped segment that
later evolved into a fully detubularized sigmoid neobladder. Satisfactory results
with this technique were described by the Minnesota group and others [1,2].
Kock was the first (1969) to construct a continent low pressure ileal reservoir.
The first (1979) who anastomosed ileum to the urethra were Camey and Le
Duc [3,4]. These techniques were modified and incorporated by Hautmann
(1986) and many others [5,6,7]. Good functional outcome of this technique
was reported by the Hautmann group [8,9].
Whether an ileum or sigmoid configuration is used depends on the availability
of bowel segments, the physical and physiological characteristics of bowel
when it is incorporated in the urinary tract, and the preference of the surgeon.
We report the long term continence rates and compare urodynamic results of
an ileal [9] and a sigmoid orthotopic neobladder constructed with a short distal
segment of sigmoid [10].
Materials and methods
Patient Selection
From 1988 to 2000, 112 male patients underwent radical cystoprostatectomy
for bladder carcinoma and construction of an orthotopic continent urinary
reservoir at our institutes. Criteria for a bladder substitution were: absence of
bladder neck invasion or prostatic infiltration, patients’ compliance, normal
renal function and a good previous continence status. Relative
contraindications were the presence of a diffuse Carcinoma in situ (Cis) and
lymph node metastases. Fifty patients received a sigmoid neobladder (SN) at
the Hospital dr Negrin, Las Palmas de Gran Canaria, Spain. In 62 patients an
ileal neobladder (IN) was created at the University Medical Centre, St.
Radboud, Nijmegen, The Netherlands.
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Thirty-four patients with a SN [mean age: 64.4 (range 51 to 76) years], and 20
with an IN [mean age 57.8 (range 30 to 78) years] agreed to postoperative
urodynamic evaluation at a median time after surgery of 18 (range 12 to 26)
and 37 (range 9 to 106) months, respectively.
Surgical technique
The SNs were constructed as previously described by Isorna et al [10]. The SN
is constructed out of a distal sigmoid segment, 18 to 20 cm long, detubularized
and single folded. The ureters were implanted through submucosal tunnels to
prevent reflux [10].
The operative technique of constructing an IN has been described in detail by
Hautmann et al [4]. The same technique was used in all patients with an IN. A
small bowel segment 40 to 60 cm long is resected 15 cm proximal to Bauhin`s
valve. The isolated small bowel segment is detubularized and arranged in a W-
shape to create the urinary reservoir. In contrast to the Hautmann technique
we performed uretero-ileal anastomoses which were direct and without an
attempt to prevent reflux.
Urodynamic evaluation
The patients started with a free uroflowmetry and were catheterized afterwards
to empty the reservoir and determine the amount of post-void residual (PVR)
urine. The patients were placed in supine position on a couch or sitting during
the investigation. An urodynamic catheter (Nijmegen: 8F double-lumen
equipped with a distal microtransducer. Las Palmas: 10F double-lumen) was
positioned via the urethra inside the neobladder to monitor pouch pressures
and fill the reservoir. A similar (single lumen) catheter was inserted 10 cm into
the rectum to record the abdominal pressure. The position of the catheters was
checked by identical response to a Valsalva maneuver. Perineal patches for
electromyography were placed to register pelvic floor activities. The pouch was
filled at a rate of 50 ml/min with sterile water of 20ºC until any one of the
following occurred: discomfort, leakage, or a volume of 1000 ml was reached.
Neobladder sensations during filling reported by the patient were marked.
While the pouch was moderately full patients were asked to perform various
Valsalva maneuvers (coughing and abdominal pushing) to check for stress
incontinence. Compliance is expressed as increase in bladder volume per
centimeter of water increase in pressure (ml/cm water) and is calculated at
maximum capacity as ΔV/Δp, where ΔV is the volume increment and Δp is 
the change in pressure. Pressure spikes above baseline due to spontaneous
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pouch contractions were recorded, if present. At maximum capacity, patients
were asked to void into an uroflowmetry device with the urethral catheter in
place.
In order to perform voiding, patients had to stand up and walk to the device.
Again stress incontinence during this maneuver was checked. The emptied
volume was regarded as the maximal volume capacity. PVR was calculated
(volume infused – volume voided).
Clinical Evaluation
Each patient was evaluated with a questionnaire and interview with regard to
their continence and voiding pattern or habits. Urinary incontinence was
defined according to the International Continence Society: the involuntary loss
of urine, which is objectively demonstrable, and a social or hygienic problem
[11]. Excretory urography (IVU) or ultrasound and laboratory findings during
follow up (blood urea nitrogen (BUN), plasma creatinin, electrolytes and acid-
base balance) were evaluated. Results were reported as mean and range.
Student’s t-test was used for statistical analysis. p < 0.05 was defined as
statistically significant.
Results
Urodynamic Evaluations
Free uroflowmetry
All but one patient could void spontaneously and performed free
uroflowmetry. The results of free uroflowmetry are shown in Table 5.1.
Table 5.1. Free uroflowmetry in 53 patients
SN (n=34)
mean (range)
IN (n=19)
mean (range)
Maximal flow rate (ml/sec) 16.6 (9 - 25.2) 16.4 (9 - 31.8)
Voided volume (ml) 234 (52 – 974) 321 (119 - 707)
Post void residual volume (ml) 62 (0 - 250) 44 (0 - 400)
The patient who could not void required clean intermittent catheterization
(CIC) 4 times a day to empty his (ileal) neobladder. At the moment of the
assessment a PVR higher than 100 ml (but less than 250 ml) was objectivated
in 8 (24%) of the patients with a SN and in 2 (10%) of the patients with an IN.
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The PVR in all but one of these patients remained stable or diminished
without clinical signs or infections and CIC was therefore not necessary. The
one (IN) patient who is on CIC performs CIC every 6 hours because of a PVR
up to 400 ml. In the majority of cases the flow curves had an intermittent
pattern.
Table 5.2. Urodynamic findings during filling
SN
mean
(range)
IN
mean
(range)
pa
Maximum bladder capacity (ml) 296
(68 - 554)
546
(208 -1116)
<0.001
Empty bladder pressure (cm
water)
48
(0 - 62)
23
(0 - 45)
<0.001
Pressure at maximum capacity
(cm water)
58
(16 - 99)
41
(13 - 70)
<0.001
Compliance (ml/cm water) 11
(2 - 24)
34
(11 - 84)
<0.001
Maximal amplitude
spontaneous pouch contractions
(cm water)
42
(14 - 75)
38
(10 - 123)
NS
Duration of contraction (sec) 40
(5 - 50)
57
(14 - 197)
NS
Patients with contractions (%) 77 90 NS
Number of pressure waves (if
present)
3 (1 - 10) 4 (1 - 10) NS
Onset of contractions
before half of maximum capacity
61% 65% NS
NS = not significant (p > 0.05)
aStudent`s t-test
Filling cystometry
Data are shown in Table 5.2. During filling of the reservoir the mean increase
in pressure from basal to pressure at maximal capacity was higher (57 cm
water) in the SN than in the IN (20 cm water, p < 0.001). The average
reservoir capacity of the SN (296 ml) was lower than the IN (546 ml, p<
0.001). Compliance was also lower in the SN (10.5 ml/cm water) than in the
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IN (35 ml/cm water) and again the difference was statistically significant (p<
0.001).
Neobladder sensations (e.g. cramping, vague abdominal fullness) were reported
during a pressure wave in 41% of the events in patients with a SN and in 71%
of the events in IN patients. Nine (26%) patients with a SN patients lost urine
during a pressure wave. This was seen in 5 (25%) patients of the IN group. A
positive stress-test was seen in 4 (12%) SN and 1 (5%) IN patients. Comparing
the two groups, no significant differences were found with regard to presence
of neobladder contractions, onset and number of contractions, mean
amplitude of the pressure waves and mean duration of contractions. In both
groups the amplitude and length of the pressure wave did not change
significantly with time. Besides that, the appearance of the waves was not
rhythmical and the frequency did not increase with filling (Fig. 5.1).
Voiding cystometry
The 53 (34 SN and 19 IN) patients who could void after urodynamics
appeared to do so by a series of Valsalva maneuvers accompanied by pelvic
relaxation. This relaxation was demonstrated by a decrease in
electromyographic activity of the pelvic floor. The mean maximum flow was
lower for patients with a SN (16.6 ml/sec) than patients with an IN (25.5
ml/sec).
Table 5.3. Urodynamic findings during voiding
SN
mean
(range)
IN
mean
(range)
pa
Maximal flow rate (ml/sec) 16.6
(7 - 32)
25.5
(5 - 35)
NS
Maximal voiding pressure
neobladder
(cm water)
48
(11 - 118)
166
(100 - 245)
<0.001
Post-void residual (ml) 62
(0 - 225)
93
(0 - 245)
NS
NS = not significant (p > 0.05)
aStudent’s t-test
Mean PVR was 62 ml in patients with a SN and 93 ml in patients with an IN.
At voiding the pressure within the pouch increased intermittently. The mean
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maximum pressure in the SN reservoir was 48 cm water and 166 cm water in
the IN (Table 5.3).
Clinical Evaluation
Voiding diary
The frequency of voiding ranged from 4 to 12 times (mean 6 times) for SN
patients and 3 to 12 times (mean 6 times) for IN patients during the day.
Patients voided when they had the sensation of fullness in the lower abdomen.
All but one (98%) of the SN and IN patients preferred sitting rather than
standing during micturation.
Table 5.4. Urodynamic parameters of night continent and incontinent patients
SN (n=34) IN (n=20)
continent incontinent pa continent incontinent pa
Number
of patients
3 31 12 8
Mean capacity
(ml)
301 296 NS 533 556 NS
Presence
of
contractions
66% 88% NS 75% 100% NS
Mean number
of
contractions
8
(6 - 10)
3.4
(1-10)
NS 3.6
(1-10)
4
(2-6)
NS
Mean
amplitude of
Contractions
(cm water)
35 41.5 NS 37 57 0.0
1
Volume at
first
contraction
44 %
(11-83)
46 %
(10-85)
NS = not significant (p > 0.05)
aStudent’s t-test
Continence status
By our strict definition, 18 of 20 (90%) IN patients and 29 of 34 (85%) were
continent during the day. Fifty percent (10 of 20) of all IN patients and 56%
(19 of 34) of all SN patients were absolutely dry and had no need for pads.
Eight of the remaining 10 (40% of all) IN patients and 10 of the remaining 15
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(29% of all) SN patients reported stress incontinence requiring the use of one
(safety) pad per day. The pad was dry to slightly damp and this was not
experienced as a hygienic or social problem. Five of the remaining 15 (15% of
all) SN and 2 (10% of all) of the remaining 10 IN patients had social and
hygienic problems related to daytime incontinence and the use of pads. Of 34
SN patients 3 (9%) and of 20 IN patients 12 (60%) were continent at night.All
3 (100%) SN patients and 8 of the 12 IN patients (67%) who were dry during
the night had to get up to remain dry. The average number of voids required
during the night was 1 for both groups. All patients who were incontinent had
hygienic problems. None of the 31 SN patients who were incontinent during
the night agreed to practice or try a wake-up regimen. All preferred the use of
pads or condom catheters. Urodynamic parameters of nighttime continent and
incontinent patients are presented in table 5.4.
Fig. 5.1. Ileum Neobladder contractions during filling cystometry.
Comparing nighttime continent and incontinent patients, no significant
differences were found with regard to mean capacity and number of
EMG
P neobladder
P abdomen
P neobladderwall
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contractions in the SN and IN group separately. However, the mean amplitude
of spontaneous neobladder contractions was statistically significant higher
(p=0.01) in the nighttime incontinent IN group.
Laboratory
No severe metabolic disturbances were detected. There was no significant loss
of renal function. Only one SN patient presented a subclinical mild acidosis
compensated with low dose of bicarbonate. Laboratory findings are presented
in table 5.5.
Radiology
No or only slight dilatation of the upper urinary tract was found. There was no
evidence for loss of renal units in both ileum and sigmoid neobladders.
History
Clinical pyelonephritis developed in 10 cases (8 of 50 [16%] in the SN and 2 of
62 [3%] in the IN group). All 12 patients were treated with antibiotics.
Table 5.5. Laboratory findings (mean levels)
SN IN
Creatinine (mg/L) 11.1 11.5
Na+ (mmol/L) 140.3 142.2
K+ (mmol/L) 4.4 3.9
Cl- (mmol/L) 103.8 105.6
HCO3
- (mmol/L) 25.5 22.1
pH 7.41 7.40
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Discussion
Patient selection
The two groups of patients are only comparable in regard to pathology and
indication to perform cystectomy and create an intestinal neobladder.
Therefore, the authors caution the reader for the inbalance between the studied
groups.
The difference in percentage of patients studied (32% of IN patients and 68%
of SN patients) has several explanations. Cultural differences concerning either
patients or physicians could partially explain this phenomenon. Furthermore,
due to the fact that urodynamic studies were performed at different times after
surgery (at a mean time of 18 months for the SN group and 37 months for the
IN group), a smaller amount of patients from the IN cohort was available,
because approximately 50% of patients with invasive bladder cancer die of
metastatic disease within 2 years.
Surgical issues
The sigmoid colon as a continent voiding pouch offers potential advantages as
well as disadvantages. Potential disadvantages are, for example, that the
sigmoid colon is often affected by diverticulosis and/or malignancy. For these
reasons it might not be a suitable bowel segment for long-term urinary
diversion. However, because of its location in the pelvis, the ureteral
anastomosis is relatively simple and due to the facility with which the sigmoid
colon can be brought to the membranous urethral region, the use of sigmoid
colon has distinct advantages over other bowel segments [12]. Furthermore,
the loss of the sigmoid colon has little if any impact on the nutritional status or
bowel habits of the patient. Ileum does not have the potential disadvantages of
sigmoid colon. The metabolic consequences are much less outspoken and the
anatomic disadvantages of an IN are easy to overcome in experienced hands
[13].
Controversy still exists on the question of whether an antireflux mechanism
should be incorporated with the orthotopic neobladder. In general, an
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antireflux mechanism should be constructed if high pressure is expected within
the reservoir to prevent pressure-induced damage of the upper urinary tract
and infections to ascend [14]. In the SN and the IN groups, different
techniques were used. A submucosal tunnel and a direct end-to-side
anastomosis were used in SN and IN groups, respectively. The low incidence
(3%) of pyelonephritis, low incidence (<1%) of upper tract dilatation on an
IVP or ultrasound, no increase in serum creatinin and no loss of renal units in
the non-antireflux (or IN) group indicates that an antireflux mechanism is not
absolute obligatory. In the non-antireflux group the upper urinary tract is
protected by a high capacity reservoir (mean 546 [range 208 to 1116] ml) with
low pressure (mean 41 [range 13 to 70] cm water) and consequently good
compliance (mean 34 [range 11 to 84] ml/cm water) during filling. During
micturition the upper urinary tract is protected by compression of the ureters
caused by the Valsalva maneuver. Only during spontaneous neobladder
contractions (mean 38 [range 10 to 123] cm water) the upper urinary tract is at
risk in the non-antireflux group. Probably the duration (mean 57 [range 14 to
197] sec) of the contractions is too short and the frequency too low to cause
dilatation of the upper urinary tract and subsequent kidney deterioration.
Continence
The subjective success of an orthotopic bladder replacement largely depends
on the degree of continence that the patient is able to achieve. Continence and
voiding patterns in the neobladders are mainly conditioned by the urodynamics
of the neobladder and by the preservation of the sphincter mechanism. The
daytime voluntary micturition after a neobladder is achieved by a combination
of floor pelvic relaxation and abdominal strain at the moment that the
involuntary pressure waves signaling the limit of wall compliance appear [15].
In most of the series daytime incontinence is not a major problem after
bladder substitution. The reported incidence of daytime continence in patients
with an orthotopic urinary reservoir is 80 – 100% [8,9,12,13]. In our series the
daytime continence rate was satisfactory in both groups in spite of the lower
capacity of the sigmoid neobladder.
Conversely nighttime incontinence affects more patients. Large series showed a
nighttime continence rate of 66 – 97% [8,9,12,13]. In our series and with strict
definitions only 9% of patients with a SN and 60% of patients with an IN were
continent at night.
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Several factors contribute to nighttime incontinence. If the functional
neobladder capacity is lower than the nocturnal output and the patient is not
aware of the (new) sensation of bladder filling, incontinence might appear. The
significant lower SN capacity (mean 296 ml) and subsequent low compliance
are probably important factors in nighttime incontinence of the SN group. An
alarm clock can be used at night for these patients, but none of the 31
incontinent SN patients was motivated to use this method. It is unlikely that
the adequate IN capacity (mean 556 ml) would contribute to loss of urine
during the night for the IN group.
If the neobladder pressure supersedes the closure pressure of the external
sphincter and pelvic floor incontinence occurs. Patients remain continent
during the day by intentionally increasing the tonus of the pelvic floor during a
bowel contraction but a reduced level of consciousness during sleep makes it
impossible to increase the tonus of the pelvic floor [16]. Besides that, it was
found on urodynamics that the intraurethral closure pressure decreased to 20
cm water during sleep with a Kock pouch bladder replacement [17]. In
controversy with other authors who postulate frequency and amplitude of the
peristaltic waves as a cause of nocturnal incontinence [18,19] we could not find
significant difference in the presence or number of neobladder contractions
between nighttime continent versus nighttime incontinent patients in the group
of patients with an IN. The small number of patients with satisfactory
nighttime continence in the SN precludes any extrapolation for this group. The
amplitude of neobladder contractions is statistically significant (p=0.01) higher
in nighttime incontinent IN patients (57 versus 37 cm water). In our study, the
pressure of the bowel contractions and not the frequency might contribute to
nocturnal incontinence in the IN.
The thicker walled colon is less compliant than ileum. Nighttime incontinence
in the SN group might be improved by increasing the volume and raise the
compliance of the pouch. A higher volume can be reached by using a larger
segment of colon. Multiple taeniamyotomies can reduce the wall tension and
internal pressure and so may improve compliance of SN [20].
The elimination or decrease of pressure of contractions may be the most
critical factor in improving nighttime continence rates in the IN group. A
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solution for this problem might be the use of a smooth muscle relaxant such as
mebeverine [21].
The need for CIC after IN varies broadly (5 to 25%) in literature. This
variation can be explained by the different cut-off of PVR at which CIC is
advised [22,23]. The CIC rate for all our IN patients was 4 of 62 (6%) and 1 of
20 (5%) for the urodynamic evaluated IN group in this study. CIC has not
been described after SN. Whether this is due to its inexistence or to the
scarcity of reports on SN remains unknown. The rate of CIC in this study is
low, but comparable with other studies [8,24].
Conclusions
A neobladder constructed from detubularized ileum or sigmoid achieves
adequate capacity with a satisfactory daytime continence rate (90% vs. 85%).
The nighttime continence rate of SN is low (9%) due to a limited functional
bladder capacity. Nighttime incontinence in patients with IN (40%) can at least
partly be explained by periods of high pressure due to neobladder contractions
in combination with a relaxed sphincter during sleep. While ileal neobladder
meets the functional day and night requirements for a bladder substitution the
sigmoid neobladder hereby described should be reserved for those patients
able to comply with a nocturnal incontinence.
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Chapter 6
The effect of N-acetyl-L-cysteine on the viscosity of ileal
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Abstract
Objective: N-acetyl-L-cysteine (NAC) proved to be an effective mucolytic in
pulmonary secretions. Our goal was to investigate the in vitro effect of NAC
on viscosity of ileal neobladder mucus.
Methods: The urine of a patient with an ileal neobladder was collected during
the first 7 days postoperatively and stored in a refrigerator. After precipitation,
the urine was decanted. The residue was stirred to a homogeneous suspension.
To samples of 4.5 ml mucus, 0.5 ml NAC l0% was added. To the control
sample, 0.5 ml water was added. The samples were incubated in a water bath at
37°C for 5, 30 and 60 min. Viscosity was measured in the Bohlin VOR
Rheometer.
Results: The viscosity of the ileal neobladder mucus decreased quickly after
incubating with NAC 10%. Viscosity increased slightly after 1 h of incubation.
The viscosity in the control sample was higher than in the other incubated
samples.
Conclusion: NAC was found to decrease the viscosity of ileal neobladder mucus,
supporting the in vivo experience that NAC can be useful in patients with an
ileal neobladder to facilitate the evacuation of mucus by decreasing viscosity.
Introduction
The concept of utilizing cysteine derivates for mucolytic therapy was
introduced by Sheffner in 1963. Extensive work revealed that N-acetyl-L-
cysteine (NAC) was an effective mucolytic [1]. Since then, NAC is the most
widely used mucolytic drug and has been documented more often as having
greater effectiveness than any other mucokinetic agent. NAC was mainly used
for lysis of sputum in patients with pulmonary diseases, such as cystic fibrosis,
bronchitis, emphysema and silicotuberculosis [2]. NAC was also shown to be
effective in preventing post-operative atelectasis [3]. Instilling 10%-20% NAC
solution was sometimes helpful in cleaning mucous sinuses and fistulas and in
debriding wounds contaminated with mucus. The solution has been given
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orally or by enema to loosen inspissated bowel mucus in cases of meconium
ileus in children with cystic fibrosis [4].
There have been three case reports published about using NAC in the urinary
tract. Benderev described utilizing NAC for the relief of mucinous obstruction
of the distal ureter after mid-ureteral replacement with ileum [5]. Using NAC
in two patients with acute ureteral obstruction secondary to mucoid impaction
in supravesical diversion was reported by Caponegro et al. [6]. Haupt et al., on
the other hand, claimed that mucus production in bowel neobladders cannot
be sufficiently influenced pharmacologically [7].
Mucus production by mucoid secretory cells in the small bowel that is used for
urinary diversion or continent ileal reservoirs is well known [8]. Since using
NAC in patients with ileal neobladders is routine in our clinic, complications
like ureteral or urethral obstruction are never seen. However, to our knowledge,
the effect of NAC on viscosity of ileal neobladder mucus has not been
described before. We investigated the effect of NAC on ileum neobladder
mucus to support our view that NAC has the capacity to facilitate the
evacuation of mucus by decreasing viscosity.
Materials and methods
The ileum neobladder of one patient was rinsed for 7 days. The urine was
collected and stored in a refrigerator. After precipitation, the urine was
decanted. The remaining fluid was kept on a magnetic stirrer until a
homogeneous suspension was formed. Precipitation, decanting and stirring
were repeated. Reproducibility of this method was tested in an earlier stage
(unpublished data). In the suspension, flakes of different shape and size were
seen. Test tubes were filled with 4.5 ml of the suspension. To the control
sample, 0.5 ml water was added. To the other samples, 0.5 ml NAC 10% was
added. NAC 10% was used because the bioavailability after oral dosing of
NAC is approximately 10% [9,10]. The samples were incubated for 5, 30 and
60 min in a water bath at 37°C. Apparent viscosity (η*) is the ratio of shear 
stress (δ) to shear rate (γ). In formula: η*= δ/γ. In the Bohlin VOR Rheometer, 
shear stress of the samples was measured at different shear rates. Apparent
viscosity was calculated.
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Results
It was observed macroscopically that the flocks in the suspension became
smaller during incubation with NAC. Viscosity at different shear rates (in
mPas) was calculated. The mean values are shown in Table 6.1.
Table 6.1. Viscosity of ileal neobladder mucus in mPas at different shear rates
Shear rate
(l/s)
Control 5 min NAC 30 min NAC 60 min NAC
14.2 53.9 41.6 34.5 44.7
17.9 41.1 31.3 20.5 29.4
22.5 31.9 19.5 16.6 25.2
28.3 24.6 15.1 13.6 20.8
35.7 17.7 11.5 10.2 16.3
44.9 14.5 10.2 9.9 13.4
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Fig. 6.1. The mean viscosity at different shear rates in control sample and other samples
after 5, 30 and 60 minutes of incubation with NAC 10%.
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The mean viscosity at different shear rates for the control sample and for
samples after 5, 30 and 60 min incubation with NAC 10% are presented in
Figure 6.1. The viscosity of the ileal neobladder mucus decreased rapidly after
incubating with NAC l0%. After 1 h of incubation, viscosity increased slightly.
The viscosity in the control sample was higher than in the other NAC
incubated samples.
Discussion
Mucus layers are found in each of the hollow organs that are in close contact
with the outer world. These layers form a selective barrier between the lumen
of the organ and the vulnerable epithelium. Mucus layers are composed of
mucins. In the gastrointestinal tract, at least eight different mucins (MUC1 to
MUC8) have been identified.
COOH COOH
| |
NH2 -C-C- - S-S-C NH2 -C – C- -S-S-C
| | | | | |
HS SH S S S S
| | | |
S S S S
| | | |
C-S-S- -C - C - NH2 C-S-S- and so on
| |
COOH COOH
Fig. 6.2. MUC2 polymer composed of monomers by disulfide bonds.
The small intestine predominantly expresses MUC2 and MUC3. MUC2 is
goblet cell specific and secretory. MUC3 is a membrane-associated mucin
specific to enterocytes. MUC2 monomers polymerize by creating disulphide
bonds into large polymers that are characteristic of secretory mucins (Fig. 6.2).
These molecules can extend to very long thread-like structures more than 10
μm in length. This great length contributes to their intrinsic viscosity and gel-
forming properties [11,12].
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N-acetyl-L-cysteine has a free sulfhydryl group capable of reducing the
disulfide bonds in mucins (Fig. 6.3). As a result, the mucin polymer is broken
into smaller, less viscous units.
MUCOPROTEIN COCH3 MUCOPROTEIN COCH3 COCH3
●●●●●●●●●●●● | ●●●●●●●●●●●● | |
| NH | NH NH
S | SH | |
| + 2 HS - CH2 – CH HC-CH2 -S-S- CH2-CH
S | SH | |
| COOH | COCH3 COCH3
●●●●●●●●●●●● R ●●●●●●●●●●●●
MUCOPROTEIN N-Acetylcysteine MUCOPROTEIN N-N-Diacetylcysteine
Fig. 6.3. Action of NAC on mucoprotein molecules
Stress is required to deform a liquid at a certain de formation rate. The ratio of
stress to deformation rate is called viscosity. For the simple type of liquid, a
Newtonian liquid, shear rate (γ) is linear proportional to the applied stress (δ): 
δ a = ηγ, where η is the Newtonian viscosity. Examples of Newton liquids are 
water, tea, coffee, alcohol and pasteurized milk. Many liquids, however, contain
polymers, such as proteins or carbohydrates and suspended micro particles.
The polymers and particles cause non-Newtonian behavior in the fluid,
meaning that the viscosity is a non-linear function of the shear rate. The
apparent viscosity (η*) defined as: η* = δ/γ is now a function of the shear rate: 
η*=f(γ). When in a non-Newtonian liquid, η* decreases more than 
proportionally, increasing γ or decreasing δ, the liquid is called shear thinning. 
Macromolecules in a polymer solution may disentangle or align to the flow
direction of the liquid. This results in lower frictional forces and, therefore,
lower viscosity. Examples of shear thinning fluids are fruit juices, yogurt drinks
and pudding. The opposite of shear thinning is shear thickening, whereby
increases more than proportionally, decreasing γ or increasing δ. These systems 
have a large volume fraction of fine particles. Upon deformation, these
particles “obstruct each other’s pathway.” Examples are homogenized peanut
butter and wet sand. The increase in viscosity after 1 h of incubation with
NAC is possibly due to shear thickening.
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After being administered orally, NAC is readily and completely absorbed. The
maximal concentration of NAC in plasma is achieved after 1-3 h. A major part
of NAC is metabolized during its first passage in the gut wall and liver [10].
Renal clearance constituted around 30% of total body clearance. Between 13%
and 38% of the oral dosage is recovered in the urine within 24 h. NAC is
quickly excreted and t½ (serum half-life) is approximately 1.5 h. As the dosing
interval (12 h) is more than five eliminated half-lives, no accumulation of
plasma concentration is expected [13]. No significant accumulation was even
noted after repeated doses of suckable tablets 200 mg every 2 h [13,14].
Adverse effects are very uncommon. In rare cases, an anaphylactoid reaction
occurs after NAC has been intravenously administered. Manifestations include
fever, rash, angioedema, hypo tension and bronchospasm. This can be
prevented or treated with an antihistaminic drug [15]. There is a possible effect
of NAC on the high-density lipoprotein (HDL) system. An unexplained
significant rise of HDL cholesterol after oral administration of 1200 mg a day
or more was observed [16]. NAC is only contraindicated in patients with peptic
ulcers and phenylketonuria. There fore, oral administration seems to be safe
with no side effects and sufficient urine concentration. In ileal neo bladders
with severe mucus production, NAC can also be instilled to increase the
mucolytic effect.
We showed that NAC is an effective mucolytic for ileal neobladder mucus in
vitro. This supports the clinical observation that NAC has an effect on the
viscosity of ileal neobladder mucus. Because oral administration is safe, we
prescribe NAC to all of our patients with an ileal neobladder for 6 months.
During the first 2 months, NAC is taken three times a day at 200 mg; then two
times a day at 200 mg during the following 2 months, and, finally, once a day at
200 mg during the last 2 months. 1f there are problems with evacuating mucus,
we continue NAC in a dosage that is sufficient for that specific patient.
The secretion of mucus can be dramatically increased in response to an acute
threat to the epithelium or in chronic pathological situations. The constant
exposure to the urine of the neobladder is one such chronic situation and leads
to morphologic changes in ileal reservoir mucosa [17]. No significant change
was observed 3 months after the operation. After 6 months, the number and
height of the microvilli were reduced. This process was completed after
approximately 1 year, decreasing the absorptive function of the intestinal
mucosa [18]. A relative increase in goblet cell number was evident after 6
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months, continued in the following 18 months and stopped thereafter. This
confirms the clinical observation that, on long-term follow-up, the mucus
secretion tends to be constant [19]. The increase in goblet cells results in a shift
in secretive pattern towards sialomucins [20]. This shift in secretion probably
makes the mucus less viscous and, therefore, NAC was not necessary for most
of the patients after 6 to 18 months.
Conclusion
NAC was found to decrease the viscosity of ileal neobladder mucus. We
believe that NAC can be useful in patients with an ileal neobladder so as to
facilitate the evacuation of mucus by decreasing its viscosity.
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Abstract
Objectives: To evaluate if the failure of chemotherapy in patients with regionally
metastatic or unresectable urothelial cell carcinoma (UCC) of the bladder can
be predicted early in the course of chemotherapy with magnetic resonance
(MR) imaging.
Methods: In this prospective study, 36 patients with regionally metastatic or
unresectable UCC of the urinary bladder underwent MR imaging before and
after two, four and six cycles of chemotherapy with Methotrexate, Vinblastine,
Adriamycin (doxorubicin) and Cisplatin (MVAC). The response after two
cycles of MVAC was evaluated by using conventional tumor size parameters at
unenhanced MR imaging and with changes in the time to the start of tumor or
lymph node enhanced at fast dynamic contrast-enhanced MR imaging. The
results obtained with these techniques were compared with the findings at
histopathology in cystectomy or transurethral resection specimens obtained
after completion of chemotherapy. Duration of survival was defined as time
from start of chemotherapy until disease specific death. Kaplan-Meier curves
were drawn to determine the difference in prognosis between responders and
nonresponders.
Results: After two cycles of chemotherapy, the accuracy, sensitivity and
specificity in distinguishing responders from nonresponders with conventional
MR imaging were 69%, 81%% and 50%, respectively. With the fast dynamic
contrast enhanced technique, accuracy, sensitivity and specificity were 92%,
91% and 93% respectively. The median bladder cancer specific survival was 28
months for all patients studied. Responders to chemotherapy at fast dynamic
contrast enhanced MR had a better median disease specific survival than
nonresponders [42 vs. 12 months (p<0,0001)].
Conclusion: It is possible to predict whether a patient will respond to
chemotherapy, after two cycles of chemotherapy with fast dynamic contrast
enhanced MR imaging.
Introduction
Urothelial cell carcinoma of the bladder is an important cause of death in the
Netherlands, with the Netherlands Cancer Registry estimating an incidence of
28 per 100.000 persons and a mortality of 13 per 100.000 men [1]. About 20 to
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30% of all patients with bladder cancer initially present with tumors invading
into or beyond the bladder muscle [2]. Treatment and prognosis is largely
determined by depth of tumor infiltration (T), the absence (0) or presence (+)
of lymph node (N) and distant metastases (M) [3]. The standard treatment for
patients with stage II (T2N0M0) and III (T3N0M0) is extended pelvic lymph
node dissection with radical cystectomy [4]. However, about 50% of these
patients have occult distant spread at diagnosis and will develop metastatic
disease within 2 years [5]. Patients with stage IV (T4N0M0, TanyN+M0,
TanyN0M+, TanyN+M+) only have a 5-year survival rate of 10% [1]. The
only chance for improvement in survival of stage IV patients is chemotherapy.
Various chemotherapeutic drugs have been reported to have activity in patients
with metastatic bladder cancer. Combination chemotherapeutic regimens are
superior to single-agent therapy. Investigators at the Memorial Sloan-Kettering
Cancer Center (MSKCC) initiated in 1983 a trial in patients with metastatic
urothelial carcinoma using the Methotrexate, Vinblastine, Adriamycin and
Cisplatin (MVAC) regimen and reported objective remissions in more than
70% of treated patients with a median survival of 13 months. Since then the
clinical experience with MVAC for stage IV bladder cancer has grown
extensively. Overall response rates of 40 to 72% and complete response rates
of 19 to 45% were reported. The durability of response is disappointing in all
series [6-8].
Significant toxicities, primarily leucopenia, culture-negative fever at the time of
granulocytopenia, sepsis and mucositis are associated with MVAC combination
chemotherapy. Side effects such as, nausea, vomiting, malaise and alopecia are
common. Besides that, chemotherapy is expensive. Early assessment of
therapeutic efficacy and prediction of failure of this treatment would help to
decide to stop at an early phase and, therefore, reduce unnecessary morbidity,
improve quality of life and decrease costs.
The effect of therapy can be evaluated noninvasively with MR imaging or
computed tomography (CT) by measuring tumor size. However, tumour
reduction after two cycles of MVAC does not always correspond with
response after completion of six courses. Fast dynamic contrast enhanced MR
imaging does not only show tumor size but also tumour neovascularization,
because of increased uptake of contrast agent. In musculoskeletal cancer, fast
dynamic contrast enhanced MR imaging proved to be accurate in the
evaluation of the effect of chemotherapy [9].
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The purpose of this study was to determine whether failure of MVAC
chemotherapy in patients with regionally metastatic or unresectable urothelial
cell carcinoma of the bladder can be predicted early in the course of
chemotherapy with MR imaging.
Materials and Methods
In this prospective study, 40 patients (33 men and 7 women, aged 35 to 78
years [mean, 56 years]) with stage IV (all≥pT2, all N1-2) UCC of the bladder
underwent contrast enhanced and unenhanced MR imaging before and after
two, four and six cycles of MVAC. Patients were hospitalized monthly for each
cycle and received MVAC according the protocol by Sternberg et al [6].
The target for MR assessment was the primary tumor in patients with positive
lymph nodes after pelvic lymphadenectomy and primary tumor and lymph
nodes for the other patients. On the unenhanced MR images, the response to
chemotherapy was determined by using conventional size parameters.
According to existing chemotherapy protocols in our hospital, a patient was
considered to be a responder if the tumor had a > 50% decrease in the
summed products of the longest perpendicular diameters of all measured
lesions without simultaneous increase in size of any lesion or appearance of
new lesions and a nonresponder if this was not the case.
Gadopenteate dimeglumine (Magnevist; Schering, Berlin, Germany) was used
as contrast in the fast dynamic contrast enhanced MR imaging. During
intravenous bolus injection of Magnevist (0.1 mmol per kg of body weight) 60
images were acquired in the section in which the tumor and, if present,
enlarged lymph nodes were optimally visualized, with one image per 1.25
seconds. With the fast dynamic contrast enhanced MR imaging, the beginning
of contrast enhancement of tumor or lymph node was determined in the most
rapidly enhancing area. In a previous study, it was demonstrated that urinary
bladder cancer started to enhance within 10 seconds (mean, 6.5 seconds ± 3.5
[standard deviation]) after the artery started to enhance [10]. The image on
which the descending aorta started to enhance was considered the reference
image at time zero. Therefore, a threshold of 10 seconds was used to
differentiate viable malignant tissue from residual nonmalignant tissue. If the
start of enhancement changed from within 10 seconds after arterial
enhancement to later than 10 seconds after arterial enhancement the patient
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was considered to be a responder. The patient was considered to be a
nonresponder if the enhancement continued to start within 10 seconds.
Imaging results were correlated with histopathological findings after
cystectomy (n=16) or transurethral resection (n=20). A patient was considered
to be a responder if at cystectomy no or only a few microscopic areas of viable
tumor were present, or if at repeated transurethral biopsy no viable tumor at all
was found. Sensitivity, specificity and accuracy were calculated for fast dynamic
contrast enhanced MR imaging and unenhanced MR imaging.
Disease specific survival was measured from the start of chemotherapy until
bladder cancer specific death. Patients known to be alive were censored at the
last contact date. To analyze differences between responders and non-
responders to chemotherapy survival curves were plotted using the Kaplan-
Meier product limit method. Survival curves were drawn for responders and
non-responders at enhanced and unenhanced MR imaging. Differences
between survival curves were assessed with the log rank test. All analyses were
performed using the MedCalc software package (version 8.1.1.0).
Table 7.1. Results of Fast Dynamic Enhanced MR imaging after two MVAC cycles
MR Imaging
Response No Response Total
Response
(T0)
20 2 22
No Response 1 13 14
Pathology
Total 21 15 36
Numbers are numbers of patients
Results
Of 40 patients entered four were excluded from final analysis for the following
reasons: progression of disease during chemotherapy and cancellation of
treatment (two), enterovesical fistula associated with poor condition and
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cancellation of treatment (one), distant metastases after six cycles of MVAC
and no histopathology available (one). Thus, 36 patients were evaluable for
response. In 22 (61%) of the 36 patients, histopathology showed complete
response of the primary tumor (T0) after completion of chemotherapy. In 14
nonresponding patients viable tumor areas (T+) were detected by
histopathology.
Table 7.1 and 7.2 show the results of both imaging techniques for the primary
tumor after two MVAC cycles. Fast dynamic contrast enhanced imaging
yielded correct results after two MVAC cycles in 33 of 36 cases. The sensitivity,
specificity and accuracy of MR imaging in distinguishing responders from
nonresponders after two MVAC cycles with the use of size criteria alone were
81%, 50% and 69% respectively. With rate of enhancement criteria, these
numbers were 91%, 93% and 92%, respectively.
Table 7.2. Results of Unenhanced MR Imaging after two MVAC cycles
MR Imaging
Response No Response Total
Response
(T0)
18 4 22
No Response 7 7 14
Pathology
Total 25 11 36
Numbers are numbers of patients
The positive predictive value for unenhanced and enhanced MR imaging was
72% and 95%, respectively. The negative predictive value for unenhanced and
enhanced MR imaging was 64% and 87%, respectively.
After four MVAC cycles, nonresponders could be distinguished from
responders in all cases. In 15 cases, persisting early enhancement after two
MVAC cycles was seen, which corresponded correctly with histopathologically
proved lack of response after chemotherapy in 13 cases. The two
histopathologically responding patients with persisting enhancement after two
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cycles had both a large (T4), poorly differentiated tumors with nodal
metastases. The enhancement after two MVAC cycles was just below the
threshold of 10 seconds and after four MVAC cycles the enhancement started
late (> 10 seconds) in both cases. The MR images of the patient who showed
response at fast dynamic contrast enhanced MR imaging and no
histopathologically response were reviewed and early enhancement (or no
response) was found.
Months since start chemotherapy
Fig. 7.1. Kaplan-Meier survival curve comparing nonresponders (-) and responders (--) to
chemotherapy at fast dynamic contrast enhanced MR imaging.
The median survival for the total study population was 28 months (range 6 to
126). Only 6 patients are still alive without evidence of disease, 41 to 126
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months after starting chemotherapy. The remaining 30 patients all died of
metastatic disease.
Figure 7.1 shows the Kaplan-Meier survival curve comparing responders with
non-responders to chemotherapy at fast dynamic contrast enhanced MR
imaging. The responders have a statistically significant better survival than the
non-responders (p<0,0001). The median survival for responders and non-
responders was 42 (range 12 to 126) and 12 (range 6 to 19) months,
respectively.
Months since start chemotherapy
Fig. 7.2. Kaplan-Meier survival curve comparing nonresponders (-) and responders (--) to
chemotherapy at fast dynamic contrast enhanced MR imaging.
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The survival curve for responders and non-responders at unenhanced MR
imaging (Fig. 7.2) shows a similar pattern with a better survival for responders
(p=0.01). The median survival for responders was 42 (range 9 to 126) months
and for non-responders 15 (range 6 to 82) months.
Discussion
Tumor cells cannot grow as a mass above 2 to 3 mm3 because diffusion is
insufficient for oxygen and glucose requirements, unless the tumor induces
blood supply. The mechanism of induction of new blood supply from the pre-
existing vascular bed is called angiogenesis or tumor-associated
neovascularization. Angiogenesis involves degrading of underlying basement
membrane, endothelial cell proliferation, migration and formation of tubular
structures with associated changes in the extracellular matrix allowing a new
vessel growth towards the tumor. Tumor-associated neovascularization is
characterized by vascular dilation, vascular hyperpermeability and increased
vascular density [11]. Reduction in tumor neovascularization during
chemotherapy is an important parameter for predicting response to therapy
[12]. Fast dynamic contrast enhanced MR imaging is useful for estimating
neovascularization as the enhancement is attributed to increased vascular
density, mean vessel diameter and vascular wall permeability. This technique
may prove superior to histological methods because it is non-invasive and can
sample the whole patient and therefore the entire tumor volume. Tumors with
neovascularization show earlier enhancement compared with tissue without
neovascularization [13]. Reduction in neovascularization during chemotherapy
corresponds to a decrease in mean vessel diameter and an increase of vascular
wall permeability and therefore delayed enhancement at MR imaging. Thus, the
change from early to later enhancement during therapy is a parameter for
predicting response to therapy as was shown earlier [10]. Persisting early
enhancement is an indicator of persisting neovascularity and a sign of no or
insufficient response to therapy.
The number of complete responders (61%) in the present study is high
comparing with data in literature (19-45%) [6-8,14]. Differences in patient
selection and techniques used to determine response may account for the
variability in response. Sternberg et al. reported a median survival for complete
responders of more than 38 months and a median survival for partial
responders and nonresponders of 11 and 8 months, respectively [6]. These
results are comparable with the median survival of 42 months for complete
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responders and 12 months for non-responders in the current study.
So, survival only improved if complete response was achieved. These results
justify the use of chemotherapy. However, chemotherapy with the MVAC
regimen is has substantial toxicity and side effects [15]. Assessment of the
efficacy of chemotherapy is important so that nonresponders can be identified
in an early stage. These patients can be protected from unnecessary additional
treatment with additional side effects and loss of quality of life. There is a
saving in costs at the same time.
The results of this study indicate that the decision regarding the continuation
of chemotherapy could have been made correctly in 33 of 36 patients after
only two MVAC cycles and in all patients after four cycles. The correct
decision would have been made in only 25 of 36 patients if only unenhanced
imaging technique had been used. The two `false-negative` persisting early
enhancement after two MVAC cycles may be explained by high tumor volume.
Dynamic enhanced MR imaging correctly showed late enhancement in these
patients after four MVAC cycles. The one `false-positive` delayed
enhancement appeared to be a nonresponder after review of MR images. If we
correct this `false-positive` into `true-negative` the positive predictive value of
fast dynamic contrast enhanced MR imaging becomes 100%. This means that
all responders at contrast enhanced MR imaging were histopathologically
responders. The practical consequences of these findings are obvious. Patients
who respond at enhanced MR imaging after two cycles of MVAC can be
encouraged to complete the whole course of six cycles. The continuation of
chemotherapy in patients who do not respond at enhanced MR imaging should
be discussed with the patient. The chance that there will be a histological
response after completion of chemotherapy is very small (13%). In patients
with a large (T4) tumor, like the `false negative` patients in this study, the
decision to discontinue the chemotherapy can be postponed after four MVAC
cycles.
Neo-adjuvant chemotherapy has been studied extensively in order to improve
survival or to preserve the bladder. Large studies with prolonged follow-up
have been able to confirm modest survival benefit with this therapy [16]. The
response to chemotherapy is probably the most important predictor of survival.
The 5-year survival, in patients with muscle invasive disease, achieving tumour
downstaging to pT0 or superficial disease with neo-adjuvant chemotherapy,
was 75%. Patients with residual muscle invasive UCC after neo-adjuvant
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therapy had a 5-year survival of only 20% [17]. In a small majority of patients
with invasive bladder tumors who achieve complete response to neo-adjuvant
chemotherapy the bladder can be preserved for up to 10 years with bladder-
sparing surgery. The bladder remains at risk for recurrences or new invasive
tumors requiring salvage cystectomy [18]. The key for successful downstaging
and bladder preservation is the complete response to chemotherapy. As shown
in our study, fast dynamic contrast enhanced imaging can be helpful in
evaluating this response.
Initial chemotherapy in the presented group of patients should not be regarded
as neoadjuvant chemotherapy. It is given to downstage extensive disease, in
which case consolidation of a response with radical surgery is feasible. The
term down-staging chemotherapy is more appropriate. Workers from the
MSKCC have published their experience in 80 patients with regionally
confined metastatic disease or advanced local disease. Ten of the 34 patients
(29%) in which CR was consolidated, with radical surgery, were alive and
disease free at 5 years [19]. The 5 year survival for the patients with CR and
radical surgery in our study was 38%. Until recently M-VAC was considered to
be the standard therapy for patients with advanced bladder cancer. Other
combination regimens such as gemcitabine and cisplatin have shown similar
survival advantage to MVAC with reduced toxicity and better tolerability [20].
It is reasonable to assume that evaluation of new chemotherapy regimens with
fast dynamic contrast enhanced MR imaging is also possible. Further studies
are necessary to confirm this.
A limitation of this study is the small number of patients. Although the
differences between conventional size parameters and the dynamic parameters
are clear a larger prospective study would help to validate these results.
Conclusion
It is possible to predict whether a patient will respond to chemotherapy, after
two cycles of chemotherapy with fast dynamic contrast enhanced MR imaging.
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Introduction
Bladder cancer is the fourth most common malignancy in men and the eighth
most common malignancy in women in Europe and the United States. Each
year approximately 20 new cases per 100.000 persons are diagnosed with
bladder cancer, resulting in 5 per 100.000 persons dying from this disease
annually. It develops more predominantly in males than in females with a sex
ratio of 3 to 1 and has a peak incidence in the seventh decade of life [1,2,3].
The majority (90 to 95%) of these cancers are urothelial cell carcinomas (UCC)
of various histologic grades (WHO I to III). Some 70 to 80% of the patients
with UCC have superficial tumors, and 1 to 3% is associated with an upper
urinary tract (UUT) tumor at initial diagnosis [4,5].
The nonmuscle-invasive lesions appear as papillary tumors limited to the
mucosa (Ta) or invading the lamina propria without involving the muscularis
propria (T1) or as flat carcinoma in situ (CIS) with diffuse malignant cells
confined to the mucosa. The likelihood that nonmuscle-invasive bladder
cancer will recur is about 70% in 5 years with a peak incidence in the first year
after initial treatment. As many as 30% of these recurrent tumors present with
a higher histologic grade and about 10% progress to muscle-invasive tumor,
creating a risk for death [4].
The remaining 20 to 30% of neoplasms are muscle-invasive (≥T2) and/or
metastatic at the time of initial presentation. Stage T2 tumors extend into the
superficial (T2a) or deep (T2b) muscularis propria. Stage T3 tumors extend
either microscopically (T3a) or macroscopically (T3b) in the perivesical fat.
Stage T4 tumors extend into contiguous organs [6]. Approximately 50% of
patients with muscle-invasive bladder cancer already have occult distant
metastases, which limits the efficacy of therapy. Most of these patients develop
clinical evidence of metastases within 1 year and succumb within 2 years of
initial diagnosis [4].
Invasive bladder cancer initially spreads radically through the inner part of the
bladder wall and then circumferentially through the muscular layer. Depending
on its point of origin, it may invade perivesical fat, prostate, seminal vesicles, or
obturator internal muscle. In women, it rarely invades the uterus or cervix.
Invasion of or growth into the ureter or prostatic urethra is common, when the
tumor originates near one of these structures [7].
Imaging in the assessment of urinary bladder carcinoma
108
Invasion of tumor cells into superficial lymphatic and vascular vessels just
beneath the lamina propria causes metastatic spread of bladder cancer.
The bladder lymphatics drain to perivesical, external iliac, hypogastric and
common iliac lymph nodes. Lymphatic spread is rare in stage T1 tumors and
found in 24% of the muscle-invasive tumors.
Table 8.1. TNM Classification
TNM 2002 Histological Description
Tis Carcinoma in situ
Ta Epithelially confined usually papillary
T1 Invading lamina propria
T2a-b
Invasion of the muscularis propria
2a: superficial invasion
2b:deep invasion
T3a-b
Perivesical fat invasion:
3a: microscopically
3b: macroscopically
T4a-b
Invasion of contiguous organs
4a: prostate, vagina, uterus
4b: pelvic sidewall, abdominal wall
N0 No lymph node involvement
N1 Single ≤2cm
N2 Single > 2cm ≤5cm,multiple≤5 cm
N3 Fixed regional nodes
N4 At or above the aortic bifurcation oringuinal nodes
M0 No distant metastases
M1 Distant metastases
Lymph node (LN) metastases in patients with T2 tumors are in more than 95%
confined to the true pelvis. In patients with T3 or T4 tumors LN metastases
are seen more often (15%) outside the common boundaries for standard LN
dissection, namely at or above the aortic bifurcation [8].
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Hematogenous spread of bladder carcinoma is infrequent. If they occur, these
metastases usually appear in lungs, bones, and liver. Bony metastases are
predominantly seen in pelvic bones, upper femora, ribs and skull in that order
of frequency and always osteolytic [9].
Once the diagnosis has been confirmed by cystoscopy, transurethral surgery
and histologic evaluation, the stage of the cancer according the TNM (tumor,
node, metastasis) staging system must be determined (Table 8.1) [6]. Staging is
important because it indicates the most appropriate treatment, provides a guide
to the likely prognosis and permits assessment of the response to therapy [10,
11,12].
As clinical staging is not reliable for determining tumor extension into and
beyond the bladder wall, imaging techniques are needed [13]. In this chapter
the role of imaging in the assessment of urinary bladder cancer will be
reviewed.
Imaging
Intravenous Urography
Intravenous urography (IVU) is indicated in all patients with signs and
symptoms suggestive of bladder cancer. It is not a sensitive tool in detecting
bladder cancer because small tumors are easily overlooked. A filling defect of
the bladder is present in approximately 60% of cases. IVU can be useful in
screening the upper urinary tract (UUT) for associated urothelial tumor, but
the incidence of synchronous UUT tumor is low (about 2%) and IVU is
effective in diagnosing synchronous UUT tumors in only two third of cases
[14].
If the tumor is located near the ureteral orifice, there may be incomplete or
even complete obstruction subsequent dilatation of the urinary tract or even
decreased excretion of the kidney on that side. Ureteral obstruction at the time
of initial diagnosis of bladder cancer usually indicates muscle-invasive cancer
[15].
The development of an UUT tumor during follow-up of patients with
superficial bladder carcinoma is very rare, and therefore IVU should not be
carried out routinely. IVU is recommended in selected patient groups, such as
heavy smokers, industrial workers and those with high-risk tumors
(pT1gradeIII and/or CIS), or in presence of vesico-ureteral reflux. IVU should
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also be carried out when cytology remains positive during follow-up or tumor
progression occurs [16].
Retrograde pyelography
Retrograde pyelography (RP) is indicated if the UUT is inadequately visualized
by IVU. RP can also be used to better demarcate a filling defect found on IVU
or to delineate suspected renal pelvic and ureteric abnormality. Prior to RP
urine from the UUT can be collected for cytology. Occasionally, RP is
performed in patients in whom IV contrast material is contraindicated.
Although anaphylactic reactions to contrast material with RP have been
described, the incidence is very low [17,18].
Ultrasonography
Transabdominal ultrasound
The value of transabdominal ultrasound (TAUS) in detection of bladder
tumors is limited. Bladder tumors < 0.5 cm in diameter, regardless of location,
as well as those of any size located in the bladder neck or dome of the bladder
are difficult to detect. On the other hand, the diagnostic accuracy for tumors >
0.5 cm in size and situated on the posterior or lateral wall of the bladder is
about 95% [19]. TAUS is inaccurate in the assessment of tumor spread beyond
the bladder wall and in evaluating lymph node metastasis. In general,
ultrasound visualization is limited in obese patients and patients with air
containing bowel loops and a moderately distended bladder is necessary for
complete evaluation of the bladder wall.
Bladder tumors appear on ultrasound as echogenic lesions. The bladder wall
has a more intense echo pattern than tumor tissue, thus permitting distinction
of early superficial lesions from those invading the deeper layers of the bladder
wall. However tumors involving the superficial muscle cannot be distinguished
accurately from tumors involving the deep muscle.
Transurethral ultrasound
Transurethral ultrasound (TUUS) with high frequency (5.5 MHz) endoscopic
transducers allows better resolution and better staging. The degree of filling of
the bladder can be changed during TUUS so that fixation or muscle infiltration
may be studied. It is most valuable in determining the stage of tumor confined
to the bladder wall and appeared to be useful in monitoring the completeness
of tumor resection. The main limitations are the inabilities to discriminate
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between Ta and T1 tumors [20]. Besides that, TUUS is an invasive procedure
requiring a special transducer.
Positron emission tomography
Positron emission tomography (PET) is a noninvasive method for recording
tissue metabolism with radiopharmaceuticals. The most widely used
pharmaceutical in oncology is the radioactive glucose analogue 2-deoxy-2-[18F]
fluoro-D-glucose (FDG). After intravenous injection FDG is transported into
cells and phosphorylated by hexokinase to FDG-6-phosphate. The following
metabolic step is blocked and FDG-6-phosphate therefore accumulates
intracellularly. 18F emits positrons at this site and these undergo annihilation
reactions emitting two photons that escape in opposite directions. These pairs
of photons are detected by the PET camera that consists of ring arrays of
detectors around the patient. Transversal high-quality images reconstructed
from the data obtained show distribution of the radioactive tracer within the
registration plane. As malignant cells have an increased glycolysis, growing
tumors or metastases may be detected by FDG-PET. [21]. However, the
clinical experience with FDG-PET in bladder cancer is limited for 18F because
FDG is rapidly excreted in urine, causing an accumulation of activity in the
bladder and making visualization of tumor and/or pelvic lymph node
metastases more difficult [22,23]. Flushing the bladder with saline during
examination can diminish this problem, but does not resolve it completely.
More specific PET radiotracers, which are not excreted into the bladder would
be of use in bladder cancer.
11C labeled choline (CHOL) has recently been reported as a new PET
radiopharmaceutical for tumor detection with minimal excretion of
radioactivity in the urine [24]. Choline is one of the components of
phosphatidylcholine, an essential element of phospholipids in the cell
membrane. As malignant tumors show a high proliferation and increased
metabolism of cell membrane components, which will lead to an increased
uptake of choline, the rationale for the use of CHOL-PET in oncology is
provided [25]. The experience with CHOL-PET in bladder cancer is limited
and the potential has not been defined yet.
In general, PET may be a valuable diagnostic tool in the staging of pelvic
lymph nodes in bladder cancer and useful for identifying uncertain or
unknown metastases. It is capable of differentiating tumor recurrence from
radiation or necrosis and can play a role in the evaluation of the efficacy of
Imaging in the assessment of urinary bladder carcinoma
112
chemotherapy [26,27]. Further investigations are, however, necessary to
determine its definite value in diagnosis, staging and follow up of bladder
cancer.
Computed Tomography
The major role of computed tomography (CT) in bladder carcinoma is to stage
rather than to detect the primary tumor, since CT appearance of bladder
tumors is not specific [28]. This technique is less accurate in low stage tumors,
and its reliability increases with more advanced disease [29, 30].
Table 8.2. MRI- and CT- criteria in bladder cancer staging.
TNM CT criteria MRI criteria
Tis Not applicable Not applicable
T1
T2a
Stage T1, T2 are diagnosed
when the tumor is confined to
bladder wall with the outer
bladder wall being of normal
low signal intensity on T2-
weighed images
T2b
Interruption of low signal
intensity
bladder wall on T2-weighed
images
T3a
T1-T3a stages can not be
differentiated
T3b Irregularity, soft tissue massextending into perivesical fat
Transmural extension tumor
extension into the perivesical fat
T4 Direct invasion of adjacentorgans
Direct invasion of adjacent
organs
N+ More than 1 cm More than 1 cm
M+ Distant metastasis Distant metastasis
However, double contrast techniques as air or carbon dioxide and 30%
meglumine diatrizoate can be used to assess small mucosal lesions [31]. On CT,
bladder neoplasm appears as sessile pedunculated soft tissue masses projecting
into the bladder lumen. The tumors have a density similar to that of the
bladder wall on enhanced scans and occasionally the intra-luminal surface is
encrusted with calcium. However, due to neovascularization, these tumors may
show increased attenuation [32].
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Bladder cancer involving superficial and deep muscles usually produce focal
bladder wall thickening and retraction, but CT can not reliably differentiate
between the various layers of the bladder wall and can not, therefore,
distinguish T1 from T2a and T2b tumors (Table 18.2) [31,33]. Moreover,
evaluation of the bladder wall after transurethral resection (the primary
treatment in bladder cancer) is difficult since the reaction of the bladder wall
after the resection also appears as thickening on CT scanning. Tumors of the
anterior, posterior and lateral walls are easy to be detected and evaluated, but
difficulties arise in showing tumors at the dome and trigone because of the
axial plane imaging used routinely in body CT [33].
Table 8.3. Accuracy of Different Staging Techniques
Stage Clinical staging
Including TUR-BT
CT MRI
T0-T+ ++ - +
Tis-Ta ++ - -
Ta-T1 ++ - -
T1-T2a ++ - +
T2a-T2b 0 - +
T2b-T3a 0 - -
T3a-T3b - ++ ++
T3b-T4a - + ++
T4a-T4b - + ++
N0-N+ - + +
M0-M+ - 0/+ ++
M+ Bone marrow infiltration
T0 No malignancy e.g. scar, fibrosis, granulation tissue, hypertrophy
T+ Malignancy
++ Highly accurate
+ Accurate
0 Not accurate
- Not possible
CT is clinically useful for detecting invasion into perivesical fat (T3a and T3b),
as CT can distinguish tumors confined to the bladder wall from those
spreading into the fat [31,33].
Macroscopic extravesical extension (T3b) is characterized by poor definition of
the outer aspect of the bladder wall with an increase in density of the
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perivesical fat. When no distinct fat planes are present between the bladder and
the rectum, uterus, prostate and vagina, early tumor invasion into these
neighboring structures may be difficult to exclude [31].
Tumor invasion of the seminal vesicle should be suspected if a soft tissue mass
obliterate the seminal vesicle fat angle. This sign should be interpreted with
caution because the normal seminal vesicle angle may be lost if the rectum is
over-distended or if the patient is scanned in prone position [31,33].
CT can in addition evaluate retro-peritoneal pelvic lymph nodes.
Unfortunately, only nodal size and shape can be evaluated, which results in
limited sensitivity (76%) Spherical nodes with a diameter of greater than 10
mm or round noder with a diameter of greater than 8 mm are suspected to be
metastatic (Table 8.2) [12, 31].
Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) is superior to CT for staging urinary
bladder carcinoma (Table 8.3) [34, 35]. The multi-planar capabilities and soft
tissue characterization capabilities of MR imaging make it a valuable diagnostic
tool for visualizing the urinary bladder [35, 36].
Normal MR Anatomy
On T1-weighted images, the urine has low-signal intensity, and normal bladder
wall has an intermediate signal intensity equal to skeletal muscle (Figure 8.1a).
On these images perivesical vessels and vas deferens appear as low signal
intensity tubular structures surrounding the bladder base interspersing the
perivesical fat. On fat saturated T1-weighted images the bladder wall has a
slightly higher signal intensity than urine or perivesical fat [35, 37, 38].
On T2-weighted images the urine has a very high and the bladder a low, signal
intensity (Figure 8.1b) [35, 37, 38]. The thickness of the bladder wall varies
with the degree of the bladder distension. The normal values range from 2.9 to
8.8 mm, with a mean of 5.4 mm. When the bladder is distended, the wall
should not exceed 5 mm in thickness [36].
The perivesical fat has a high signal intensity both on T1- and on fast spin-
echo T2-weighted images, and an intermediate signal intensity on spin-echo
(SE) T2-weighted images [35, 37, 38]. On fat saturated T2-weighted images the
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signal intensity of perivesical fat is lower than that of the bladder wall. On
these images the bladder wall can only be delineated if there are adjacent higher
signal intensity perivesical venous plexus or seminal vesicles [35, 37, 38].
1a 1b
Fig. 8.1. T2b bladder cancer. On (a) T1-weighted MR-image tumor (∆) has identical 
signal intensity compared to wall. Urine has lower and perivesical fat has higher signal
intensity. On (b) T2-weighted MR image urinary bladder tumor has higher signal intensity
than bladder wall, and lower than urine. At arrows low signal bladder wall is disrupted by
tumor, which argues for at least deep muscle invasion (T2b).
Immediately after injection of gadolinium-contrast (Gd) intravenously, the
urinary bladder wall shows rapid enhancement [39]. Differential enhancement
between the inner mucosa and submucosa, and the outer muscular layer has
been reported on early images. The inner layer is more vascular and shows
early enhancement while the less vascular muscular layer enhances later [36,
39]. About 2 minutes after contrast injection the gadolinium-contrast is
excreted into the urine. In order to visualize enhancement within the bladder
wall, these images must be acquired before the mixture of contrast and urine
reaches the bladder, so within 2 minutes. Patent blood vessels with normal
flow can be recognized without intravenous contrast by its typical signal void
on turbo or fast SE images [40].
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flow can be recognized without intravenous contrast by its typical signal void
on turbo or fast SE images [40].
On T1-weighted images lymph nodes have an intermediate signal intensity
(Figure 8.2).
On T2-weighted images, the signal intensity varies (Figure 8.3). It is, however,
always higher than that of muscle. T1-weighted images provide the optimal
contrast between intermediate signal intensity nodes and high signal intensity
fat [12].
2a 2b
Fig. 8.2. Normal lymph node.
On (a) coronal T1-weighted image imaging plane of (b), parallel to psoas muscle
(“obturator” plane) is indicated by white line. On (b) T1-weighted “obturator” plane a small
3 mm normal node (arrow) can easily be separated from longitudinal running vessels. On this
T1-weighted image node has lower signal intensity compared to fat.
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Optimizing MR Imaging of Urinary Bladder
Several factors must be considered when trying to optimize MR images of the
urinary bladder. These factors are related both to the patient and the technique.
Fig. 8.3. Metastatic enlarged nodes (arrows).
On T2-weighted image nodes have higher signal intensity compared to muscle, and identical
signal intensity compared to bladder cancer.
Numerous artifacts are important: the most important are motion-artifact
reduction [41], and the degree of bladder filling [38]. Bowel motion can be
reduced by glucagon or hyoscine butylbromide (Buscopan) intravenously
before and during examination. Respiratory movements can be restricted
wrapping an adjustable belt around the patient’s abdomen. Optimal distension
of the bladder will improve evaluation of the wall and tumor. An empty or
scarcely filled bladder can be avoided by asking the patient to drink 2 glasses of
water and refrain from voiding 2 hours before the examination.
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Selection of appropriate pulse sequences, use of surface coils and of contrast
agent must also be considered when trying to improve image quality [10]. In
general, axial images should be acquired using T1- and T2-weighted sequences
followed by imaging in other planes, depending on the site of the tumor [10,
33]. Use of multi-planar reconstruction with a 3D sequence gives the best
results. An important plane direction in evaluating lymph nodes is parallel to
the psoas muscle. This so called “obturator plane” allows visualization of
nodes along their long axis, and can locate them in relation to the iliac vessels
and obturator nerve (Figure 8.2). The slice thickness should be 4 mm at the
most, with a gap of maximal 1 mm. A thinner slice thickness produces better
anatomical details and improved partial volume. Image quality in the pelvis
should be improved by using surface coils. Phased array body coils are well
suited for pelvic MRI [38].
4a 4b
Fig. 8.4. Bone marrow metastases (arrows).
On (a) post-Gd fat sat T1-weighted image, due to enhancement bone marrow metastases can
be recognized as high signal intensity lesions. On (b) T1-weighted MR image metastases can
bee seen as low signal intensity round lesions.
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Since MRI is a highly flexible and versatile system, many different imaging
sequences and imaging planes are used for pelvic scanning. The choice will
depend largely on the type of the scanner used and its ability to obtain fast
images. However, irrespective to the scanner features, T1- and T2-weighted
sequences are mandatory [10, 38]. T1-weighted images are used to determine
tumor infiltration into the perivesical fat; these sequences are most suitable for
imaging lymph nodes as well. In addition there is a good contrast between
bony metastasis and surrounding fatty bone marrow. For T2-weighting turbo
or fast SE sequences are considered state of the art. These sequences are used
for determining depth of tumor infiltration within the bladder wall, for
differentiating tumor from fibrosis, for assessment of invasion into the
prostate, uterus or vagina and for confirming bone marrow metastasis seen on
T1-weighted images (Figure 8.4a).
Urinary bladder carcinoma develops neovascularization [42, 13, 43-48]
therefore after intravenous administration of Gd, bladder cancer shows earlier
and more enhancement than normal bladder wall or other non-malignant
tissues. Urinary bladder cancer starts to enhance 7 seconds after the beginning
of arterial enhancement which is at least 4 seconds earlier than most other
structures [42]. Contrast enhancement has many advantages including:
improved detection of small bladders tumors, especially those measuring < 1
cm that may be missed on T2-weighted images because the high signal tumor
can be obscured by urine; improved differentiation of bladder tumors from
blood cloth and other debris; improved detection of muscular and perivesical
fat invasion [49]; improved conspicuity of (small) vessels. For contrast
enhanced imaging of bladder cancer T1-weighted sequences with a time
resolution of less than 20 seconds should be used. In the early (first pass)
phase discrimination between cancer and wall or fibrosis is best visible. To
enhance tumor visualization in the perivesical fat, either subtraction or fat-
saturation must be applied.
Bladder Cancer Staging
Local tumor extension, the degree of lymph node and distant metastases, and
histologic tumor type largely determine treatment and prognosis. Therefore,
exact staging is imperative. To determine local tumor extension (T), presence
of lymph node (N) and distant metastases (M) the International Union against
Cancer proposed a uniform clinical staging method (Table 8.1) [6].
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Tumor staging
Because conventional clinical staging -bimanual examination under anaesthesia,
cystoscopy and TransUrethral Resection of the Bladder Tumor: TURBT)- is
not reliable to determine tumour extension beyond the bladder wall, other
methods such as CT and MRI are needed. Indeed, CT cannot, reliably
differentiate between the various layers of the bladder wall and cannot
distinguish between superficial (Ta-T1) and muscle invasive (T2) disease.
5a 5b
Fig. 8.5. Papillary stage T1 tumor with stalk (arrowhead).
On (a) T2-weighted tSE image low signal intensity muscle is not disrupted by higher signal
intensity tumor. In the center of the papillary tumor a low signal intensity stalk (arrowhead)
can be seen. This stalk has on (b) post-Gd fat sat T1-weighted image more enhancement
compared to the rest of the tumor (arrowhead). Courtesy: E Abou-Bieh, Mansoura, Egypt.
Since the introduction of pelvic MR imaging in 1083, several reports have
shown superiority of this technique for staging urinary bladder carcinoma [50-
52].
Bladder tumors demonstrate different patterns of growth: papillary, sessile,
infiltrative or mixed pattern. Papillary tumors are usually superficial (Ta or T1)
and are best demonstrated on T1-weighted images in which the intermediate
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signal intensity of the intra-luminal tumor is outlined by surrounding low signal
intensity urine. On T2-weighted images, the signal intensity of both bladder
tumor and intravesical urine increase and intra-luminal projections of bladder
tumors may be less conspicuous than on T1-weighted images. Papillary TCC
of the bladder has a loose connective tissue stalk. The identification of the stalk
of a polypoid tumor, which has a lower signal intensity than tumour on T2-
weighted images, may be an important observation to exclude muscle wall
invasion of the tumor (Figure 8.5) [53].
Findings suggestive of superficial (T1) tumors are on T1-weighted post
contrast images: smooth muscle layer, tenting of the bladder wall, fern-like
vasculature and uninterrupted submucosal enhancement (figure 8.6a/b) [54].
Findings Suggesting Superficial Tumors
Definitive Criterion Ancillary Criteria
Smoothe mucle layer Tenting of Fern-like Uninterrupted
the bladder wall vasculature submucosal
enhancement
Fig. 8.6a. Staging Bladder cancer (MRI). Findings suggestive of superficial (T1) tumors
are on T1-weighted post contrast images: smooth muscle layer, tenting of the bladder wall,
fern-like vasculature and uninterrupted submucosal enhancement.
Muscle wall infiltrative tumors (≥T2) present as a diffuse or focal thickening of
the bladder wall with increased signal intensity on T2-weighted images. This
higher signal intensity is in contrast to the low signal intensity of normal
bladder wall [37]. Early contrast enhanced images may help to recognize
muscle wall infiltration. Findings that suggest muscle invasion are: irregular
wall at the base of the tumor, focal wall enhancement or wall thickening
around the tumor (Figure 8.7) [54].
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Muscle wall invasion is separated into superficial (T2a) and deep (T2b). In
stages T2b the low signal intensity layer of the bladder wall is disrupted on T2-
weighted images by the higher signal tumor (Figure 8.1b). Stage T2b cannot be
separated on MRI from stage T3a (microscopic fat infiltration). Macroscopic
tumor extension through the bladder wall into the perivesical fat (stage T3b)
will cause a focal irregular decrease of signal intensity of the fat on standard
T1- or T2-weighted images. Contrast enhanced images with fat saturation also
show tumor (enhancement) in the perivesical fat. Invasion of adjacent organs
may be inferred from the extension of abnormal tumor signal intensity through
fat planes into adjacent structures.
Fig. 8.6b. Staging Bladder cancer (MRI). Findings suggestive of superficial (T1) tumors.
This is well demonstrated with contrast enhanced images. Invasion of the
seminal vesicles can be demonstrated by an increase in vesicular size, decrease
in signal intensity on T2-weighted images and obliteration of angle between the
seminal vesicle and the posterior bladder wall. Invasion of the prostate and
rectum is seen as direct tumor extension with an increase of signal intensity.
Obliteration of the angle between bladder and prostate also indicates prostate
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invasion. Invasion of the pelvic side-wall (T4b) is seen on T1-weighted images
as a loss of normal fat plane between bladder wall (tumor) and the vessels or
musculature of the sidewall, or on T2-weighted images as invasion of the
sidewall musculature in by intermediate to high signal intensity tumor.
Multiplanar imaging allows better visualization of the bladder dome, trigone,
and adjacent structures such as the prostate and seminal vesicles. The accuracy
of MR imaging in staging bladder cancer varies from 73 to 96%. These values
are 10 to 33% higher than those obtained with CT [51]. Recently several
reports have been published on the staging of urinary bladder carcinoma with
the use of intravenous Gd-contrast. A 9% to14% increase in local staging
accuracy has been reported using these contrast agents. Furthermore, when
using contrast agents, visualization of small tumors (>7 mm) improves and
tumour can be differentiated from post-biopsy effects with an accuracy of
90%[42]. The most accurate staging results using Gd-contrast material are
obtained with very fast T1-weighted sequences [54]. This can be explained by
earlier enhancement of tumors compared to surrounding tissues.
Findings Suggesting Muscle-Invasive Tumors
Definitive Criterion Ancillary Criteria
Irregular wall Focal wall Wall thickening
at the base enhancement around the tumor
of the tumor
Fig. 7a. Staging bladder cancer (MRI). Findings that suggest minimal muscle invasion
(T2a) are; irregular wall at the base of the tumor, focal wall enhancement, and wall
thickening around the tumor.
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A tumor in a bladder diverticulum can be a problem for imaging. TUUS is of
value detecting tumors in a diverticulum, especially if the mouth of the
diverticulum is not accessible for cystoscopy. Multi-planar MR imaging can
demonstrate the presence and precise location of the bladder diverticular neck.
Also, the intrinsic tissue contrast of both the T1- and T2-weighted images
allows differentiation of urine and tumor, showing the intra-luminal extent of
tumour [56].
Lymph node staging
Lymph node metastasis in patients with nonmuscle-invasive tumors (<T2) are
rare, but if the deep muscle layer is involved (T2) or if extravesical invasion is
seen (T3-4), the incidence of lymph node metastasis rises to 20 to 30% and 50
to 60%, respectively. Detection of lymph node metastases has very important
clinical consequences. If metastatic disease is present, at least an extended
lymph node dissection should be performed in order to maximize the curative
intent of radical cystectomy. A noninvasive, reliable method for detecting and
staging nodal metastasis could allow modification of the extent of node
dissection. Currently, there are five imaging techniques described for nodal
staging: lymphangiography, ultrasound (US), CT, MRI, and PET-scanning.
Fig. 8.7b. Staging bladder cancer (MRI). Findings that suggest minimal muscle invasion
(T2a) (Irregular wall at the base of the tumor, focal wall enhancement and wall thickening
around the tumor).
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Lymphangiography, US and CT
Bipedal lymphangiography is no longer used as imaging method, although it
has the capacity to show micro metastases in normal-sized nodes. Its inability
to depict internal iliac nodes and its invasiveness are major drawbacks. US and
CT are have a too low sensitivity to reliably detect all lymph node metastases
[57]. CT scans fail to detect nodal metastases in more than half of patients with
proven positive nodes [58].
MRI
Normal nodes down to a size of 2 mm can be recognized with MRI. With
multi-planar imaging both size and shape of the nodes can be assessed. The
maximal length (long axis) and the minimal axial size of the node can be
determined. Round nodes can be distinguished from oval nodes by using an
index by dividing the axial size by the long axis. Lymph nodes are considered
rounded when this index is in between 1.0 and 0.8 and are spherical or
elongated if this index is <0.8. The cut-off value for a pathologic node is a
minimal axial diameter of 10 mm for a spherical/elongated node and 8 mm for
a rounded node. An asymmetric cluster of small lymph nodes also is
considered to be pathologic [12].
Current imaging techniques can only show nodal size. Different sensitivities
and specificities are acquired depending on the selection of cut-off size for
lymph nodes [59]. Recently Jager and coworkers showed that with a three-
dimensional (3D) high-resolution technique, not only nodal size but also nodal
shape could be assessed [12]. Using the nodal shape in relation to the cut-off
size improved their results with an accuracy of 90% and a positive predictive
value of 94% [11]. This is clinically relevant as a high positive predictive value
in the detection of nodal metastasis can also facilitate the indication for (MR-
guided) biopsy [60]. In case of a positive biopsy this may cause a change of
treatment from surgery to initial chemotherapy. Cross-sectional imaging
modalities like CT and (3D) MR imaging have a low sensitivity (76%) as
metastases in normal size lymph are still missed, since both modalities use the
non-specific criterion of size to distinguish between normal and malignant
nodes [12, 59]. Although fast dynamic MRI has shown to improve sensitivity
by showing fast and high enhancement in metastatic nodes, specificity
decreases. In addition, application of fast dynamic techniques is further limited
by its low resolution and pronounced vascular artifacts [42].
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PET
Although very promising in metastatic lung cancer [61], the role of FDG-PET
scanning is limited in the assessment of pelvic lymph nodes. In a study using
PET in 64 patients with urinary bladder cancer, Bachor et al. obtained a
sensitivity of 67% and a negative predictive value of 84%. In addition, their
reported specificity of 86% is lower than those obtained with CT and MRI
[62]. Heicappell et al. obtained with their data a sensitivity of 65% [63]. Thus
the accuracy of FDG PET-scanning is not high enough to replace pelvic
lymph node dissection (PLND). The value of PET with other positron-
emitting radionuclides needs to be evaluated. Staging PLND still remains the
most sensitive method for assessing lymph node metastases, and thus
continues to be the first step in the management protocol of patients with
muscle-invasive cancer and no visceral metastasis.
Distant Metastases
Currently, the mainstay for the detection of bone metastases is a radionuclide
bone scan. However, MR imaging is superior to 99mTc bone scan in
assessment of bone marrow involvement [64]. The high sensitivity of MRI for
evaluating bone marrow metastasis makes it an ideal tool for detecting
suspected osseous metastatic disease and determining its extend [65,66].
Osseous metastases are generally hematogenously spread, and the vascular
bone marrow is usually the earliest site of involvement. For purposes of
screening T1-weighted images are adequate to detect foci of abnormal marrow.
Therefore, MR imaging can be useful in the evaluation of patients suspected of
having vertebral metastases with equivocal or negative bone scans. Thanks to
its high spatial resolution MR imaging may also guide needle biopsy
procedures. Plain radiographs are the least sensitive in evaluating the axial
skeleton for metastases in that 50% of bone mineral content must be altered
before there is evidence of metastases is visible. The limitation of MR imaging
however is the inability to produce “whole body” images.
New Techniques
Multidetector row CT Urography
During the past few years CT has challenged IVU in the evaluation of the
urinary tract. Unenhanced helical CT is more sensitive than either IVU or US
for the detection of urinary stones [67,68]. Contrast-enhanced helical CT is
well established as being more sensitive and specific in the detection and
characterization of renal masses [69]. Until recently, the only remaining
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advantage of IVU over CT has been its ability to depict intra-luminal filling
defects and mucosal abnormalities in the upper urinary tract. Recent
improvements in CT hardware have led to the development of the multi-
detector (MD) row (or multi-slice) CT scanner. Multi-detector row CT
urography (MDCTU) offers single breath-hold coverage of the entire urinary
tract and high resolution images. Multiple thin overlapping slices provide
excellent 2D and 3D reformatted images.
The ability of MDCTU to detect urothelial tumors in the renal collecting
system or in the ureter has not been thoroughly evaluated or established in the
literature. Caoili and co-workers reported that 6 of 6 proven urothelial
malignancies in the renal pelvis and ureters were detected by MDCTU [70].
IVU has been reported in the literature to have detection rates for urothelial
neoplasms of only two-thirds of cases [14]. MDCTU seems to perform at least
as well as IVU in detecting UUT. Moreover, on MDCTU the urinary tract
distal to an obstructing lesion is also well demonstrated, thus overcoming the
limitations of IVU in a non-functioning kidney with obstructive disease [71].
Other advantages of MDCTU over IVU include identification and
characterization of the causes of ureteric obstruction including short segment
malignant strictures with associated mural thickening, retroperitoneal masses
and lymphadenopathy, retroperitoneal fibrosis, benign ureteric strictures and
iatrogenic causes such as posthysterectomy and postcolectomy injuries [72,73].
Evaluation of the bladder by MDCTU requires pre-and postcontrast studies.
The pre-contrast study is useful as calcifications within the bladder wall or
lumen are easily detected. Focal bladder wall calcification can occur with
carcinoma of the bladder. However, bladder masses frequently cannot be
detected on noncontrast images. Focal areas of bladder wall thickening or
masses that protrude into the bladder lumen suggest bladder carcinoma,
particularly when it is associated with greater enhancement than the adjacent
bladder wall. Kim et al. evaluated the accuracy of MDCTU in the detection and
staging of bladder cancer. Bladder cancers show peak enhancement to
approximately 106 ± 14 HU (Hounsfield units) with 60-second delayed
scanning. A detection rate of 97% (75/77) for all bladder cancers and 85%
(11/13) for bladder cancers < 1 cm was reported. Sensitivity and specificity in
the diagnosis of perivesical invasion in this study were 89 and 95%,
respectively [74]. MDCTU seems to be useful in the detection and staging of
bladder cancer. Therefore, at most academic medical institutions, MDCTU has
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replaced IVU as the diagnostic imaging study of choice for the evaluation of
patients with hematuria (or suspected urolithiasis).
USPIO MRI
Previous reports have shown that the information about lymph nodes on MR
images can be improved by pharmaceutical manipulation of tissue proton
relaxation times. Ultrasmall superparamagnetic iron oxide (USPIO) particles
with a long plasma circulation time have been shown to be suitable as a MR
contrast agent for intravenous MR lymphangiography [75, 76].
8a 8b
Fig. 8.8. Normal size (5 mm) metastatic node in hypogastric region (circle). CT-
reconstruction in “obturator” plane shows normal size (5 mm) node (circle). On (b) T2*-
weighted MR image (sensitive to Iron) in identical plane obtained 24 hrs post-USPIO this
node (circle) has high signal intensity which argues for metastasis. Also 2 small normal black
nodes (arrows) are visible, which have low signal intensity due to accumulation of iron loaded
macrophages in normal nodal tissue.
After intravenous injection the USPIO particles are transported to the
interstitial space and from there they are transported through the lymph vessels
to the lymph nodes. Once within normally functioning nodes the iron particles
are taken up by macrophages and reduce the signal intensity of normal lymph
node tissue in which they accumulate, because of the T2- and susceptibility
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effect of iron oxide, and this produces a negative enhancement. In areas of
lymph nodes that are involved with malignant cells, macrophages are replaced
by cancer cells, which lack reticuloendothelial activity and are unable to take up
the USPIO particles (figure 8.8). The uptake may also be decreased in
inflammatory nodes. In addition, because of increased vascular permeability
and increased diffusion in cancer tissue, there is leakage of USPIO particles
into the metastatic areas, which produces a low local concentration and
nonclustering of USPIO particles at these metastatic sites [76]. Through their
T1 relaxivity this can induce an increase in signal intensity on T1-weighted
images, producing positive enhancement [77-79].
Thus the ability of post USPIO MRI to identify metastatic areas in the lymph
nodes depends primarily on the degree of uptake of USPIO by the
macrophages in normal lymph node tissue and the leakage of USPIO particles
in the metastatic area itself. Twenty-four hours after intravenous injection of
USPIO normal lymph node and malignant tissue have different signal intensity
on MR images (figure 8.8), and thus this noninvasive technique may result in
the detection of metastatic normal-size nodes [80].
Papers describing this technique in the evaluation of pelvic malignancies report
a sensitivity of 82 to100% [79-82]. Other papers include lymph node
evaluation in other areas, predominantly head and neck, and chest. Reported
sensitivities (mean 91%, variation 84 to100%) are higher compared to pre
contrast MRI [83-86]. As these authors did not use high resolution techniques,
they had limited visualization of small (< 8 mm) lymph nodes. In a study
performed at UMC in Nijmegen and Massachusetts General in Boston [81], in
80 patients with histological proven prostate cancer, using high-resolution
techniques (at 1.5 T using a body phased-array coil), on post-USPIO MRI the
rate of detection of small nodal metastases in normal 5 to 8 mm sized nodes
was significantly improved. Sensitivity and accuracy and negative predictive
value showed a significant improvement using post-USIOP to 100%, 98% and
100% respectively. This was due to the detection of small 3 to 4 mm
metastases in normal-sized nodes. In addition in 9 out of 80 patients, nodes
were found outside of the surgical field. During the slow (30 minute) infusion
of the USPIO-contrast only 2 patients showed minor side effects (low back
pain), which was due to a too rapid infusion. After slowing down the infusion
rate the symptoms decreased, and no further treatment was needed. In a
similar study of bladder cancer post-USPIO results, MRI was associated with
sensitivity, specificity, accuracy, negative and positive predictive value of 96%,
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95%, 95%, 89%, and 98%, respectively [87]. A proportion of patients with
node positive bladder cancer can be cured with extended pelvic
lymphadenectomy [88]. USPIO MRI can reliable map all positive pelvic lymph
nodes and guide to radical lymphadenectomy.
Virtual Cystoscopy
Recent studies reported the feasibility of 3D rendering of the bladder, which
provide an imaging format familiar to the urologist [88-90]. Bernhardt et al.
found that the finding at MR cystoscopy, as compared with those at
cystoscopy for the detection of the tumours, did not reveal a statistically
significant difference. Compared with axial images, however, CT or, MR
cystoscopy showed no significant differences in detection of papillary lesions
with a diameter ≥10 mm, and had almost the same sensitivity and specificity
as these modalities [90-92]. The clinical value of virtual cystoscopy requires
further study.
Summary and Recommendations for Imaging Approach
On the basis of published reports and our own experiences [10, 33, 35]. Table
8.3 offers an overview of the value of the several staging techniques for urinary
bladder carcinoma. MRI is superior to CT for staging as CT can not
differentiate between the various layers of the bladder wall and can not,
therefore, distinguish lesions of the lamina propria from these invading the
superficial and deep muscle wall. There are also difficulties in assessing tumors
at the dome and trigone. The multiplaner and soft tissue characterization
capabilities of MRI make it a valuable diagnostic tool among the noninvasive
imaging modalities. Also, MR imaging is the most promising technique in the
detection of nodal and bone marrow metastases. When MR imaging is
available, CT is no longer needed. In addition, recent advances of MRI such as
fast imaging, fast dynamic Gd-enhanced techniques, and the use of specific
contrast for assessment of lymph nodes improve the imaging quality and
diagnostic accuracy for staging urinary bladder carcinoma and detection of
positive nodes. However, due to limited resources this technique should only
be used to obtain information in a pre-selected subset of patients, and only
when imaging results directly influences management. To achieve this, both
knowledge of urologists of MR imaging and knowledge of radiologist of
clinical handling is required, therefore, continuous education and
communication between these two specialties is a necessity.
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Integration of Imaging and Management
Figure 8.9 outlines the diagnostic management of urinary bladder cancer.
Detection of bladder cancer should be performed by cystoscopy. Once bladder
cancer is diagnosed, the next step should be staging. For superficial tumors,
clinical staging, which includes TUR, is the best technique. If, however, there is
muscle invasion, further staging has to be performed with MRI. To avoid
postbiopsy over-staging from edema and fibrosis or the inconvenience of
waiting 2 to 3 weeks after transurethral biopsy, we recommend fast dynamic
imaging. Superficial tumors without muscle invasion (Ta-T1) are treated with
TURBT with or without adjuvant intravesical installations. If cystoscopy
reveals large multiple nodular or papillary tumors, an MRI examination can be
helpful to provide an overview of the tumor prior to the biopsy.
Patients with muscle invasion (T2a-b) and with perivesical infiltration (stages
T3a-b) or with invasion into prostate, vagina or uterus (T4a) will tried to be
cured by radical cystectomy and extended lymphadenectomy. In cases of pelvic
sidewall or abdominal wall infiltration (T4b) or metastases in lymph nodes
(N3-4) or bone marrow (M+), palliative chemo- or radiotherapy will be
considered. Follow-up for these therapies can be best monitored with fast
dynamic MR imaging [13].
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Figure 8.9. The diagnostic management of urinary bladder cancer.
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Summary
Bladder cancer is relatively common among men, in the Western world. Each
year approximately 20 new cases per 100.000 persons are diagnosed with
bladder cancer, resulting in 6 per 100.000 persons dying from this disease
annually. It develops more predominantly in males than in females with a sex
ratio of 3 to 1. This difference can be partly explained by occupational
exposure to carcinogens and cigarette smoking. Smoking is an important risk
factor leading to a two to fourfold increase in risk. Other risk factors are
chronic bladder irritation caused, for example, by urinary tract infections,
indwelling catheters, radiotherapy or chemotherapy (cyclophosphamide).
Individual genetic predisposition may partly be responsible for a considerable
part of all bladder cancers. The majority (90-95%) of these cancers are
urothelial cell carcinomas (UCC). Chronic irritation is associated with the
development of squamous cell carcinomas. This manuscript is confined to
patients with UCC.
UCC of the urinary bladder can present as a superficial (Ta-T1) or a muscle-
invasive (≥T2) tumor. The majority of patients (70 to 80%) present with
relatively benign superficial tumors. Superficial UCC of the bladder is
characterized by a high risk of recurrence (70% within 5 years), with most
recurrences in the first year after initial treatment. Approximately 10% of these
recurrent tumors progress to muscle-invasive disease. The remaining 20% to
30% of neoplasms are muscle-invasive (≥T2) and/or metastatic at the time of
initial presentation. About 50% of patients with muscle-invasive bladder cancer
already have occult distant metastases, which limits the efficacy of therapy.
Most of these patients develop clinical evidence of metastases within 1 year
and succumb within 2 years of initial diagnosis.
The treatment of muscle invasive bladder cancer without metastases (T2-
3aN0M0) is radical cystectomy with extended lymph node dissection. A
neobladder or other urinary diversion made out of an isolated bowel segment
has to be constructed hereafter. Patients with advanced disease (T4N0M0,
TanyN+M0, TanyN0M+, TanyN+M+) and good performance status are
treated with chemotherapy.
If patients with a progressive tumor can be recognized before an invasive or
advanced disease occurs, aggressive therapy can be initiated in an early stage
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and to try to improve the prognosis of the patient. Quality of life must be an
issue in very therapeutic step. This manuscript discusses some prognostic
factors in patients with UCC of the bladder, as well as aspects of quality of life.
A general introduction of bladder carcinoma is presented in chapter 1. The
subsequent chapters each discuss a separate study from this thesis. In this
summary an attempt is made to address the aims from chapter 1 on a point-
to-point basis.
Aims:
1. To study the difference in prognosis between muscle-invasive
bladder cancer patients with and without a history of superficial
bladder cancer.
Patients with primary and progressive muscle-invasive bladder without
evidence of metastases are treated equally in normal daily practice, i.e. patients
undergo extended lymph node dissection and radical cystectomy. Because
different cancer-specific survival for both patient groups was observed
clinically and timing of radical treatment for patients with high risk superficial
disease is still a controversial issue, we performed a retrospective study to
determine the difference in survival between these two patient populations.
This study is presented in chapter 2. Seventy-four patients with progressive
muscle-invasive bladder cancer from Nijmegen and Rotterdam were identified
and matched for stage with 89 patients with primary muscle-invasive bladder
cancer. The 3- and 5-year survival rates were 67% and 55% respectively for
patients with primary invasive tumor and 37% and 28% for patients with a
progressive tumor. The risk for disease-specific death in the progressive group
was about twice the risk in the primary group at all times during follow up.
Patients with muscle-invasive bladder cancer and a history of superficial
bladder cancer have a worse prognosis than patients without this history.
Therefore, in patients with recurrent or persisting high risk superficial UCC,
radical surgery should be considered seriously.
Chapter 9
145
2. To confirm the prognostic value of cell cycle regulatory proteins
p53 and p27Kip1, and cell adhesion molecule α-catenin in patients
with progressive bladder carcinoma.
Because patients with progressive disease have a worse prognosis than patients
with primary invasive disease, as mentioned in chapter 2, it is a challenge to
identify those patients who will progress in an early stage. In chapter 3, a case
control study, in which a selected group of patients with progressive UCC of
the bladder was matched on an individual basis to a group of patients with
non-progressive bladder carcinoma, to confirm the prognostic value of cell
regulatory proteins p53 and p27Kip1, and cell adhesion molecule α-catenin, is
described. Immunohistochemical status of these markers was established. An
independent odds ratio for p27Kip1, p53 and α-catenin of 0.3, 3.4 and 2.5
respectively, for progression was found. Immunohistochemical expression of
p53 and α-catenin in primary tumors do have an additional prognostic value
above clinical parameters like stage, grade and concomitant CIS.
Overexpression of immune-detectable p53 is mostly caused by p53 mutation.
Mutation analysis of p53 is the most promising prognostic marker.
3. To evaluate the prognostic value of perineural and
angiolymphatic invasion in advanced non-metastasized bladder
cancer.
One of the most important prognostic factors is the extent of the tumor.
Perineural invasion (PNI) and angiolymphatic invasion (ALI) has been
correlated with a worse prognosis in gastro-intestinal carcinoma. In chapter 4
a retrospective study of 44 patients with invasive UCC, without signs of
metastases, of the bladder who underwent radical cystectomy and pelvic lymph
node dissection is described. Pathology specimens showed PNI predominantly
(80%) in pT3b tumors. PNI does not appear to be independent of pT3 and is,
therefore, not an independent prognostic factor for survival. Patients with ALI
had a worse 3-year survival compared with patient without ALI (49 vs. 85%).
Due to the small group of patients, the prognostic value of ALI was only
borderline significant (p=0.05). ALI seems to be a predictor of disease-free
survival.
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4. To compare urodynamic and continence parameters between
orthotopic sigmoid and ileal neobladder.
Many different methods of bladder substitution have been developed in an
attempt to achieve the goal of a neobladder that functions as well as a normal
bladder. The ideal neobladder substitute should have adequate capacity, store
urine at low pressure, preserve continence, evacuate via the urethra with
minimal residual urine. Various segments of small and large bowel have been
used for neobladder construction. Whether an ileum or sigmoid configuration
is used depends on the availability of bowel segments, the physical and
physiological characteristics of bowel when it is incorporated in the urinary
tract, and the preference of the surgeon. In chapter 5 the long term
continence rates and urodynamic results of an ileal neobladder (IN) and a
sigmoid neobladder (SN) constructed with a short distal segment of sigmoid
are reported. The average reservoir capacity of the SN (296 ml) was lower than
the IN (546 ml). Daytime continence was achieved in 90% of IN patients and
85% of SN patients. Only 9% of patients with a SN and 60% of patients with
an IN were continent at night. The low nighttime continence rate of the SN is
probably related to its small functional capacity. Nighttime incontinence in
patients with IN can at least partly be explained by periods of high pressure
due to neobladder contractions.
5. To investigate the effect of N-acetyl-L-cystein (Fluimucil®) on
the viscosity of ileal neobladder mucus.
N-acetyl-L-cysteine (Fluimucil®) proved to be an effective mucolytic drug in
pulmonary diseases, such as cystic fibrosis and bronchitis. Mucus production
by mucoid secretory cells in the bowel that is used for urinary diversions or
continent reservoirs is well known. Mucoid impactation can cause ureteral or
urethral obstruction and consequent hydronephrosis or bladder outlet
obstruction. The use of Fluimucil® is controversial in urology, because mucoid
production is according to many urologists seldom problematic and the
effectiveness of Fluimucil® in urology has never been proved. Nevertheless,
some patients with a bowel reconstructed urinary tract seem to benefit using
Fluimucil®. The effect of N-acetyl-L-cystein (Fluimucil®) on the viscosity of
ileal neobladder mucus is presented in chapter 6. In cooperation with TNO,
Nutrition and Food Research Institute, (Fluimucil®) was (in vitro) found to
decrease the viscosity of ileal neobladder mucus. Fluimucil® can be useful in
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patients with a urinary diversion or continent reservoir to facilitate the
evacuation of mucus.
6. To evaluate chemotherapy with Magnetic Resonance Imaging in
patients with regionally metastatic or unresectable bladder
cancer.
Patients with locally advanced or metastatic bladder cancer die from their
disease if not treated. These patients can be treated with combination
chemotherapy (i.e. methotrexate, vinblastine, adriamycin and cisplatin [M-
VAC] in 6 cycles). Overall response rates of 40% to 72% and complete
response rates of 19% to 45% were reported. Unfortunately, the durability of
response is disappointing in all series. The median survival is more than 38
months for complete responders and 12 months for non- or partial
responders. Chemotherapy can cause significant toxicities and severe side
effects. Early assessment of therapeutic efficacy and prediction of failure of
chemotherapy would help to decide to stop at an early phase and, therefore,
reduce unnecessary morbidity and improve quality of life. The effect of
chemotherapy in patients with advanced bladder cancer is evaluated with MRI
in chapter 7. After two cycles of chemotherapy, the accuracy, sensitivity and
specificity in distinguishing responders from nonresponders with fast dynamic
contrast enhanced MRI were 92%, 91% and 93% respectively. Responders to
chemotherapy at fast dynamic contrast enhanced MRI had a better median
disease specific survival than nonresponders [42 vs. 12 months (p < 0,0001)].
The practical consequences of these findings are obvious. Patients who
respond at enhanced MR imaging after two cycles of MVAC can be
encouraged to complete the whole course of six cycles. The continuation of
chemotherapy in patients who do not respond at enhanced MR imaging should
be discussed with the patient. These patients can be protected from
unnecessary additional treatment with additional side effects and loss of quality
of life.
7. To review imaging in the assessment of bladder cancer.
Once the diagnosis has been confirmed, the size and extent of the tumor, or
stage of the cancer, must be determined. Staging indicates the most appropriate
treatment and provides a guide to the likely prognosis. Since imaging plays an
important role in bladder cancer staging the invitation to write a chapter about
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this issue was accepted with gratitude. Chapter 18 from Textbook of bladder
cancer (Seth Lerner, Mark Schoenberg and Cora Sternberg: editors) is
presented here as chapter 8. The diagnostic management of bladder cancer is
lined out. Besides that, new imaging techniques and implementation of these
techniques is described.
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Future perspectives
Molecular biology
Traditional prognostic factors to predict the clinical outcome of superficial
bladder carcinoma are tumor size, stage and grade, concomitant CIS, tumor
recurrence and multiplicity [1]. The prognostic factors for organ-confined
bladder cancer are stage and angiolymphatic invasion. However, these
prognostic factors are not accurate enough to define the risk of tumor
recurrence and disease progression.
Deregulation of cell-cycle and apoptotic pathways are necessary for
uroepithelial transformation to carcinoma. Several immunochemical molecular
markers involved in these pathways have been studied. Controversial results
have been reported in regard to the expression of different markers as
independent predictors of progression [2,3]. The lack of clarity regarding
prognostic factors may be caused by the fact that these markers rely on
assessment of individual molecules, whereas biological processes as cell cycle
regulation and apoptosis are a complex interaction of many different
molecules.
With microarray techniques it is now feasible to reveal a complete view of the
molecular biology of the tumor, rather than to elucidate a single molecule.
Microarray-based techniques array Comparative Genomic Hybridisation
(DNA), expression arrays (RNA) and protein arrays, allow the analysis of a
large number of genomic loci, genes, and gene products simultaneously. This
type of analysis will reveal differences in genomic and transcriptional profiles
between tumor types. In this way, subtypes within morphologically
homogeneous groups of tumors can be identified [4,5], although chance
findings still limit a clear distinction between signal and noise, prohibiting the
widespread clinical implementation of array-based techniques.
Nevertheless, comprehensive understanding of cell cycle (de)regulation, and
apoptosis may lead to the development of specific therapies and to the rational
selection of therapeutic modalities for a specific patient. In the near future,
such molecular tests might improve the prediction of the clinical course of
disease as well as the response to different kinds of therapy. Timing of such
treatment and determination of treatment intensity can be individualized.
Individualization of treatment will decrease side effects of treatment and
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therefore improve quality of life. Eventually, this will lead to a better bladder
cancer specific survival.
However, before genetic and/or protein profiling will become a common tool
in routine diagnostic and prognostic pathology of (bladder) tumors, a number
of important issues must be addressed. RNA-based expression profiling
requires an alternative approach to tissue handling than the traditional formalin
fixation, which is routinely used in most histopathology laboratories. Snap
frozen tissue samples will overcome this problem. Furthermore, samples of
considerable size are required in order to obtain sufficient amounts of RNA.
DNA-based tumor profiling by microarray CGH does not have these
limitations. Formaldehyde fixed, paraffin-embedded tumor specimens can be
used and relatively small biopsy samples can provide enough DNA. Ultimately,
however, DNA-based technologies are not expected to be as important as
RNA or protein-based technologies. After all, complex mechanisms drive the
transcription and translation of DNA and these mechanisms remain largely
ignored with the use of DNA-based technologies. The use of microarrays in
clinical oncology raises another critical issue: the management of the
tremendous volume of data generated in the context of different types of
analyses. To fulfill the expectations of microarray technology close cooperation
between experts in microarray technologies (molecular biologists as well as
bioinformaticians and biostatisticians) and clinicians is mandatory.
Chemotherapy
Locally advanced tumors reveal a higher risk for the development of regional
lymph node metastases due to micrometastases that are present in up to 50%
of these patients. It has been postulated that early chemotherapy, either as
neoadjuvant or adjuvant therapy in addition to radical cystectomy might
improve the overall survival by eradication of low-volume metastatic depots.
According to large meta-analyses neoadjuvant chemotherapy has some effect
on improving overall survival with a 5% absolute improvement in survival at 5
years [6]. At this time an optimal chemotherapy regimen has not been
identified. Efforts to identify patients most likely to benefit from neoadjuvant
chemotherapy are necessary.
The role of adjuvant chemotherapy in the management of muscle-invasive
bladder cancer is still unclear. Ongoing multicenter randomized trails should
define this role. Patients should be encouraged to enter these studies.
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Systemic chemotherapy is the only current modality which has been shown to
improve survival in responding patients with metastatic bladder cancer.
Combination therapy such as MVAC (methotrexate, vinblastine, adriamycin
and cisplatin) were reported with objective response rates up to 75%, with
complete responses occurring up to 35% of cases, and median survival periods
increasing from 3 to 12 -14 months. On the other hand, the MVAC regimen
induces significant toxicity with drug related deaths (3%), grade 3/4
neutropenia (82%) and neutropenic fever (14%). Therefore, attention has
turned to new drugs like gemcitabine and the taxanes (paclitaxel, docetaxel).
Studies with the two-drug combination of gemcitabine and cisplatin (GC)
produced similar results in terms of efficacy and median survival to those with
MVAC with less toxicity [7]. To date, there are no randomized data to show
that any of other new double or triple combinations of active agents improve
patient survival as compared with GC.
The treatment of metastatic cancer by chemotherapy has reached a therapeutic
plateau. There is a need for more effective treatment options. The most
interesting targets include angiogenesis and its regulation and growth factors
and their receptors.
Imaging
Recent improvements in CT hardware have led to the development of the
multidetector (MD) row or multislice CT scanner. MD row CT urography
(MDCTU) offers single breath-hold coverage of the entire urinary tract and
high resolution images. Multiple thin overlapping slices provide excellent 2D
and 3D reformatted images. MDCTU can reliable detect bladder tumors in
97% (75/77) and perivesical invasion with a sensitivity and specificity of 89%
and 95%, respectively [8]. MDCTU can detect upper urinary tract tumors in
the majority (6/7) of cases. MDCTU will replace IVU as the diagnostic
imaging study of choice for the evaluation of the upper urinary tract in patients
with superficial bladder carcinoma in all medical institutions.
The sensitivity of MDCTU is too low to reliably detect all lymph node
metastases. In more than half of patients with pathologically proven positive
nodes CT failed to detect nodal metastases. The role of positron emission
tomography (PET) with FDG (18F-fluorodeoxyglucose) is also limited in the
assessment of pelvic lymph nodes. The combination MDCTU and PET yields
a higher diagnostic and prognostic accuracy. For the diagnosis of lymph node
and distant metastases, the sensitivity, specificity and accuracy were reported to
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be 60%, 88% and 78%, respectively [9]. More studies are needed to confirm
the value of PET/CT in bladder cancer staging. The potential of other
positron emitting radionuclides, like 11C labeled choline (CHOL), may provide
better results in bladder cancer staging and needs to be evaluated.
Ultrasmall superparamagnetic iron oxide (USPIO) particles have been shown
to be suitable as a MR contrast agent for intravenous MR lymphangiography.
The sensitivity, specificity, accuracy, and negative and positive predictive in
lymph node evaluation in bladder cancer patients was 96%, 95%, 95%, 89%
and 98% respectively [10]. A proportion of patients with node-positive bladder
cancer can be cured with extended lymphadenectomy. USPIO MR imaging
may provide a reliable map of positive pelvic lymph nodes and guide a radical
lymphadenectomy.
Radical cystectomy and urinary diversion
Laparoscopy has advanced to become a significant part of urologic surgery.
The indications for laparoscopy have been progressively extended and include
nowadays the most advanced oncologic and reconstructive procedures. The
first laparoscopic radical cystectomy was performed by Parra [11] in 1992.
However, his team reached the conclusion, that this technique did not provide
any advantages over the open radical cystectomy.
Only recently, with advancements in instrumentation design and improvement
of surgical techniques, laparoscopic radical cystectomy has regained interest
[12]. In a mixed intra- and extra-corporal procedure the advantages of
laparoscopy and those of open surgery are combined. The extended bilateral
pelvic lymphadenectomy and radical cystectomy are performed by laparoscopic
approach. Then, isolation of the ileal loop, side-to-side ileal-ileal anastomoses
and fashioning of the posterior neobladder plate are done under direct visual
control. After that, the operation is continued intra-corporeal, with the urethra-
neobladder anastomosis, the uretero-neobladder anastomoses and closure of
the neobladder. Combining laparoscopic and open techniques decreases
operation time significantly and enhances safety during some critical periods of
surgery. Until now, the number of these combined technique radical
cystectomies is too small and the follow-up too short to compare oncological
and functional results with the standard open procedure. Even the combined
technique radical cystectomy is a technical difficult intervention and should be
performed in selected centers with experienced teams.
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I personally presume that growing expertise in urological laparoscopy and
further development and availability of robotic systems will shift the
population of patients with localized bladder cancer to the combined intra-
extracorporeal surgery as the future standard technique.
Multidisciplinary approach
The biggest obstacle to the proper assessment of new treatments is the
underestimation of the number of patients needed to detect medically
important treatment differences. Meta-analysis of small undersized clinical
trails should not be used to replace well-conducted, randomized clinical trials.
In order to achieve large sample sizes multicenter and multinational
collaboration is required.
Good surgical outcome is determined by many factors: proficiency of the
surgeon, appropriate skills of supporting medical, nursing and non-clinical
staff, and the overall functioning of a surgical institution. Because there is a
strong inverse correlation between increasing hospital volume and inpatient
mortality, the principle of setting a minimum threshold for bladder cancer
surgery is necessary. The minimum hospital case load to achieve the lowest
mortality rate in radical cystectomy was defined 11 cystectomies per year [13].
As stated in this thesis, treating patients with bladder cancer is more than
performing cystectomies alone. Patients with superficial high-risk or muscle
invasive bladder cancer deserve to be treated on the basis of combined
knowledge of dedicated urologists, medical oncologists, pathologists, nuclear
medicine physicians and radiologists. The only approach to this complex
disease is a multidisciplinary one.
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Samenvatting
In de Westerse wereld is blaaskanker een relatief veel voorkomende vorm van
kanker. Ieder jaar wordt bij 20 per 100.000 personen de diagnose blaaskanker
gesteld en sterven 6 per 100.000 aan deze ziekte. Blaaskanker komt vaker voor
bij mannen dan bij vrouwen (ratio 3:1). Dit verschil komt mede door de
blootstelling aan carcinogenen zoals het roken van sigaretten en beroepsmatige
blootstelling. Roken is de belangrijkste risicofactor en verhoogt de kans op
blaaskanker 2 tot 4 maal. Andere risicofactoren zijn chronische irritatie van de
blaas door bijvoorbeeld urineweginfecties, verblijfskatheters, radiotherapie of
chemotherapie. Daarnaast speelt individuele genetische gevoeligheid
waarschijnlijk een rol. De meest (90 tot 95%) voorkomende vorm van
blaaskanker is het urotheelcelcarcinoom (UCC). Bij chronische irritatie ontstaat
meestal een plaveiselcelcarcinoom. Dit proefschrift beperkt zich tot patiënten
met UCC.
Het UCC van de blaas kan zich presenteren als een oppervlakkige (Ta-T1) of
als een spierinvasieve (≥T2) tumor. De meerderheid (70% tot 80%) van de
tumoren is oppervlakkig en relatief goedaardig. Oppervlakkig UCC van de
blaas geeft een hoge kans op een of meerdere recidieven (70% binnen 5 jaar),
waarbij de meeste recidieven worden gevonden in het eerste jaar na initiële
behandeling. Progressie naar een spierinvasieve tumor treedt bij ongeveer 10%
van de recidieven op. De resterende 20% tot 30% van de tumoren is bij initiële
diagnose spierinvasief met of zonder (lymfeklier)metastasen. Ongeveer de helft
van de patiënten met een spierinvasieve tumor hebben onzichtbare
(micro)metastasen. Dit beperkt het effect van de ingezette therapie. Bij de
meeste van deze patiënten worden de metastasen binnen 1 jaar klinisch evident
en overlijdt de patiënt binnen 2 jaar na initiële diagnose.
Behandeling van de spierinvasieve tumor die zich beperkt heeft tot de blaas
(T2-3aN0M0) bestaat uit radicale cystectomie met uitgebreide lymfeklier
dissectie. Hierna kan een neoblaas worden gecreëerd van een geïsoleerd
darmsegment of een urostoma worden aangelegd. Patiënten waarbij de
blaastumor zich niet meer beperkt heeft tot de blaas (T4N0M0, Ta-4N+M0,
Ta-4N0M+, Ta-4N+M+) worden, indien de gezondheidstoestand van de
patiënt dit toestaat, behandeld met chemotherapie.
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Indien een tumor met potentie tot progressie kan worden herkend voordat
spierinvasie of metastasen optreden kan met agressieve therapie in een vroeg
stadium getracht worden de prognose van patiënten te verbeteren. Bij iedere
therapeutische stap die wordt genomen dient een realistische inschatting
gemaakt te worden van de winst die de patiënt kan behalen bij die stap. De
gevolgen voor de kwaliteit van leven worden hierbij in ogenschouw genomen.
Dit proefschrift behandelt enkele prognostische factoren bij patiënten met
UCC van de blaas, waarbij de kwaliteit van leven tevens aan de orde komt.
De verschillende studies, waarop dit proefschrift is gebaseerd, zijn in
afzonderlijke hoofdstukken beschreven. In deze samenvatting worden de in
hoofdstuk 1 genoemde doelstellingen puntsgewijs behandeld. De betreffende
hoofdstukken worden tevens uitvoeriger besproken.
Doelstellingen:
1. Het bestuderen van verschil in prognose tussen patiënten met
spierinvasief blaascarcinoom met en zonder voorgeschiedenis
van oppervlakkig blaascarcinoom.
Patiënten met primair en progressief spierinvasief blaascarcinoom zonder
aanwijzingen voor metastasen worden in de dagelijkse praktijk hetzelfde
behandeld; dat wil zeggen ondergaan een radicale cystectomie met uitgebreide
lymfeklierdissectie. Omdat vanuit de kliniek de indruk bestond dat patiënten
met een voorgeschiedenis van oppervlakkig blaascarcinoom een slechtere
overleving hebben dan patiënten zonder deze voorgeschiedenis en de vraag
wanneer er bij patiënten met een agressief oppervlakkig blaascarcinoom
radicale therapie moet worden ingezet onduidelijk is, werd hier retrospectief
onderzoek naar gedaan. In hoofdstuk 2 wordt dit onderzoek beschreven.
Patiënten (n=74) uit Nijmegen en Rotterdam met progressie van oppervlakkig
naar spierinvasief UCC van de blaas werden vergeleken met 89 patiënten met
primair spierinvasief blaascarcinoom. De patiënten met een progressieve tumor
hadden een slechtere 3 en 5 jaarsoverleving (respectievelijk 37% en 28%) dan
de patiënten met een primaire tumor (respectievelijk 67% en 55%). De kans op
overlijden aan blaaskanker bleek bij patiënten met een progressieve tumor 2
keer zo groot als in de controle groep. Patiënten met een voorgeschiedenis van
oppervlakkig UCC van de blaas blijken bij progressie inderdaad een slechtere
prognose te hebben dan patiënten met primair spierinvasief blaascarcinoom.
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Bij patiënten met recidief of persistent agressief oppervlakkig blaascarcinoom
moet radicale therapie serieus worden overwogen.
2. Het bepalen van de prognostische waarde van de celcyclus
regulatoren p53 en p27Kip1 en het celadhesie molecuul α-catenin
bij patiënten met progressief blaascarcinoom.
Omdat zoals bleek uit hoofdstuk 3 dat patiënten met progressie een slechtere
prognose hebben werd onderzocht of de tumoren die invasief worden eerder
kunnen worden herkend. In een patiënt gecontroleerde studie, waarin een
groep patiënten met een progressief oppervlakkig UCC van de blaas, op
individuele basis, werd gekoppeld aan een groep patiënten met oppervlakkig
blaascarcinoom zonder progressie, beschreven in hoofdstuk 4. werd dit
onderzocht. Immunohistochemische bepaling van celcyclus regulatoren p27Kip1
en p53 en het celadhesie molecuul α-catenin vond plaats. Een onafhankelijk
risico ratio voor p27Kip1, p53 enα-catenin van respectievelijk 0,3 3,4 en 2,5 kon
worden bepaald. Immunohistochemische expressie van p53 en α-catenin in
primaire tumoren hebben een additionele prognostische waarde naast klinische
parameters zoals tumorstadium, gradatie en de aanwezigheid van carcinoma in
situ. Sterke expressie van p53 wordt vaak veroorzaakt door mutatie van het
p53gen. Mutatie analyse van p53 blijkt een veelbelovende prognostische
marker.
3. Het onderzoeken van de prognostische waarde van vaatinvasie
bij patiënten met niet gemetastaseerd blaascarcinoom.
Eén van de belangrijkste prognostische factoren is de uitgebreidheid van de
tumor. Uit studies naar gastro-intestinale maligniteiten is gebleken dat
patiënten met tumoren met perineurale groei en/of vaatinvasie (in bloed en/of
lymfevaten) een slechtere prognose hebben. In hoofdstuk 3 wordt een
retrospectieve studie beschreven van 44 patiënten met spierinvasief
blaascarcinoom zonder aanwijzingen voor metastasen, die een radicale
cystectomie met pelviene lymfeklierdissectie ondergingen. In het
cystectomiepreparaat bleek perineurale groei voornamelijk (80%) voor te
komen bij pT3b tumoren en was daarmee geen onafhankelijke prognostische
factor. Patiënten met vaatinvasie hadden een slechtere 3-jaars overleving dan
patiënten zonder vaatinvasie (49 tegen 85%). Gezien het geringe aantal
patiënten werd geen volledige statistische significantie bereikt (p=0.05). Het
blijkt dat vaatinvasie een slechtere prognose doet vermoeden.
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4. Het vergelijken van urodynamische parameters en continentie
cijfers bij neoblazen van ileum en sigmoїd.
Vele methodes om de blaas te vervangen zijn ontwikkeld om een neoblaas te
creëren die functioneert gelijk een normale blaas. De ideale neoblaas heeft
voldoende capaciteit, kan urine bij lage druk bewaren zonder dat lekkage
optreedt en kan zonder residu via de plasbuis worden geledigd. Geïsoleerde
segmenten van zowel dunne als dikke darm worden gebruikt ter constructie
van een neoblaas. Daar onduidelijk is welk darmsegment het best gebruikt kan
worden en continentie een belangrijke rol speelt bij de kwaliteit van leven voor
de patiënt werd een vergelijkend onderzoek gedaan zoals beschreven in
hoofdstuk 5. In dit onderzoek werden patiënten met een sigmoїd neoblaas 
(SN) en patiënten met een ileum neoblaas (IN) vergeleken door middel van
urodynamisch onderzoek. De gemiddelde functionele blaascapaciteit was 296
ml voor patiënten met een SN en 546 ml voor patiënten met een IN. Overdag
was 90% van de IN en 85% van de SN patiënten continent. Mede door de
geringe capaciteit was slechts 9% van de SN groep `s nachts droog. In de IN
groep was 60% `s nachts droog. Incontinentie in de IN groep kon deels
worden verklaard door hoge blaasdrukken gedurende de nacht.
5. Het onderzoeken van het effect van N-acetyl-L-cysteïne
(Fluimucil®) op de viscositeit van slijm uit de ileum neoblaas.
N-acetyl-L-cysteïne (Fluimucil®) is een slijmoplossend middel dat zijn
werkzaamheid in de longgeneeskunde bewezen heeft en aldaar voornamelijk
gebruikt wordt bij afwijkingen zoals cystische fibrose (taaislijmziekte) en
chronische bronchitis. Patiënten met een ileum neoblaas (of andere
urinewegreconstructie met darmsegment) kunnen, omdat darm van nature
slijm produceert, hinder ondervinden van slijmproductie. Urine is hierdoor
soms moeizamer te evacueren en zelfs urinewegobstructie kan door slijm
worden veroorzaakt. Het gebruik van Fluimucil® is in de urologie omstreden.
Slijmproductie is volgens vele urologen zelden een probleem en daarnaast is de
werkzaamheid van (Fluimucil®) is bij urologische patiënten nog nooit
wetenschappelijk aangetoond. Het effect van N-acetyl-L-cysteïne (Fluimucil®)
op de viscositeit van slijm uit de ileum neoblaas is beschreven in hoofdstuk 6.
In samenwerking met TNO werd aangetoond dat N-acetyl-L-cysteïne
(Fluimucil®) de viscositeit van slijm uit de IN (in vitro) daadwerkelijk verlaagt.
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Het gebruik van N-acetyl-L-cysteïne (Fluimucil®) bij kan de evacuatie van slijm
bij patiënten met een urinedeviatie of neoblaas vergemakkelijken.
6. Het evalueren van het effect van chemotherapie bij patiënten
met niet tot de blaas beperkt spierinvasief blaascarcinoom
middels MRI.
Patiënten met blaascarcinoom dat lokaal is doorgegroeid en/of gemetastaseerd
is via lymfevaten naar de lymfeklieren of via het bloed naar bijvoorbeeld de
longen, lever of botten kunnen niet operatief behandeld worden. Deze
patiënten kunnen met chemotherapie (bijvoorbeeld een combinatie van
Methotrexaat, Vinblastine, Adriamycine en Cisplatinum [M-VAC] in 6 kuren)
worden behandeld. Onder chemotherapie wordt bij 40 tot 72% van de
patiënten een significante reductie van de tumormassa gezien. Complete
remissie (CR) wordt bij 19% tot 45% van de patiënten gezien. Deze CR is
helaas bij de meerderheid van de patiënten slechts tijdelijk. Verschil in reactie
op chemotherapie uit zich ook in verschil in overleving. Patiënten met CR
hebben een gemiddelde overleving van drie en een half jaar. Patiënten die niet
of deels reageren hebben een gemiddelde overleving van 12 maanden.
Chemotherapie is toxisch en kan vanwege ernstige bijwerkingen een zware
aanslag zijn op de kwaliteit van leven. Het in een vroeg stadium herkennen van
het effect van chemotherapie kan onnodige behandeling voorkomen. In
hoofdstuk 7. wordt het effect van chemotherapie (M-VAC) middels MRI
geëvalueerd. Uit deze studie blijkt dat na 2 van de 6 kuren chemotherapie bij
patiënten die op MRI reductie van neovascularisatie van de tumor laten zien
met 95% zekerheid voorspeld dat het voltooien van de 6 kuren zinvol is. Bij
patiënten die geen afname van neovascularisatie laten zien kan na 2 kuren met
87% zekerheid worden gesteld dat het voltooien van 6 kuren geen toegevoegde
waarde heeft. Na 4 kuren kon de uitkomst van de 6 kuren in alle gevallen met
100% zekerheid worden vastgesteld. Patiënten met complete respons op MRI
hebben een gemiddelde overleving van 42 maanden. De patiënten die niet of
deels reageren op chemotherapie leven gemiddeld 12 maanden. Deze
resultaten hebben praktische gevolgen. Patiënten die na 2 kuren op MRI
reageren, kunnen worden aangemoedigd de chemotherapie te continueren en
het tijdelijke verlies in kwaliteit van leven te accepteren. Patiënten waarbij geen
reactie wordt gezien kan dit verlies in kwaliteit bespaard blijven en kan de zorg
zich richten op palliatie.
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7. Het geven van een literatuuroverzicht naar beeldvorming bij
blaaskanker.
Stadiëring van de tumor en het aantonen dan wel uitsluiten van
(lymfeklier)metastasen is van groot belang voor het opstellen van een
individueel behandelplan. Beeldvormende technieken, die zich in een razend
tempo ontwikkelen, spelen hierbij een steeds grotere rol. De uitnodiging om
een hoofdstuk te schrijven over beeldvorming bij blaaskanker in een leerboek
over blaaskanker werd enthousiast aanvaard. Hoofdstuk 18 uit Textbook of
Bladder Cancer; editors: Seth P. Lerner, Mark Schoenberg, Cora Sternberg
komt overeen met hoofdstuk 8 van dit proefschrift. Naast een duidelijk
stroomschema voor diagnose en behandeling van blaaskanker wordt de
ontwikkeling en toepassingen van nieuwe beeldvormende technieken
beschreven.
Dankwoord
161
Dankwoord
De totstandkoming van een proefschrift is niet alleen het resultaat van de
inspanning van de promovendus. Integendeel. Velen hebben de afgelopen
jaren hun bijdrage geleverd aan de totstandkoming van dit boekje en zonder
deze hulp was dit proefschrift er nooit geweest. Bij dezen wil ik een ieder graag
bedanken die hier direct of indirect een grote of kleine bijdrage aan heeft
geleverd. Een aantal mensen wil ik hierbij bijzonder bedanken.
Prof. dr JA Witjes, beste Fred. Graag wil ik je bedanken voor het stimuleren
van dit meerjaren project. Je weet als geen ander dat sommige onderzoekers
weinig aanmoediging nodig hebben en kleine aanwijzingen soms voldoende
zijn.
Prof. dr LALM Kiemeney, beste Bart. Dank voor je statistische ondersteuning
van verschillende onderzoeken. Je snelle en vooral grondige correcties heb ik
steeds zeer gewaardeerd.
Prof. dr JO Barentsz, beste Jelle. De medische beeldvorming heeft door jou
een extra dimensie gekregen. Je bevlogenheid op (urologisch) MRI gebied
werkt zeer aanstekelijk. Dank voor de mooie plaatjes.
Prof. dr JA Schalken, beste Jack. Bij iedere presentatie (die ik waar ook ter
wereld van je hoor) verbaas ik me hoe eenvoudig je moeilijke celbiologische
processen aan een ieder duidelijk kan maken. Dank voor je uitleg en hulp.
Prof. dr FMJ Debruyne, beste professor. Tijdens de opleiding heeft u het
verhaal verteld van Sinterklaas en zijn ezel. U Sinterklaas (vreemd want er
werden in Nijmegen geen cadeautjes uitgedeeld) en ik de ezel (ook vreemd
want in Nijmegen worden alleen de aller, aller, allerbeste assistenten opgeleid).
Ik hoop dat ik met dit proefschrift het hoefdierstadium ben ontgroeid en
wacht nu op een cadeautje van de Goed Heiligman.
Dr Laguna, beste Pilar. Zowel de samenwerking in Nijmegen als het samen
werken aan het artikel over urodynamica bij neoblazen heb ik als zeer prettig
ervaren. Je bent (zoals Jean natuurlijk al wist) in veel opzichten een heel
bijzondere vrouw. Vooral je talenkennis bewonder ik zeer.
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Dr Dik, beste Pieter, kolonel! Samen hebben we in het Militair Hospitaal een
prima tijd gehad. Deden de eerste Mansoura-pouch in Nederland en zorgden
voor nogal wat opschudding met het vergroten van het geschut van een soldaat.
Jij hebt me enthousiast gemaakt voor de urologie. Ben nog steeds blij dat ik je
heb leren kennen. Je bent een fantastisch uroloog en in vele opzichten een
bijzonder mens.
Dra vd Pal, beste Floor. Je hebt de basis gelegd voor het Nijmeegse deel van
het artikel over urodynamica bij neoblazen. Je onderzoek was erg grondig en ik
heb hier veel aan gehad. Dank en succes bij je eigen promotieonderzoek.
Dr Vriesema, beste Jessica. Nooit gedacht dat p53 kleuringen en DNA analyse
zo arbeidsintensief zouden zijn. Naast goed promotieonderzoek, word je
volgens je opleider ook een prima uroloog. Dank voor je hulp en steun.
Drs Speel, beste Tommy. Het onderzoek naar vaatinvasie bij patiënten met
niet-gemetastaseerd blaascarcinoom heb jij vlot getrokken. Met wat moeite
heeft het eindelijk toch tot een publicatie geleid. Succes met je opleiding tot
uroloog.
Lieve Francien. Zonder ‘thuis’ was promoveren niet mogelijk geweest. Dank
voor je onvoorwaardelijke steun en al het andere wat ik hier niet hoef te
melden.
Lieve Frederique en Christien. Het was niet altijd goed te begrijpen dat papa,
zelfs af en toe op vakantie in Frankrijk, achter de computer kroop. Het boekje
is nu eindelijk af en de computer vrij voor Barbie.nl.
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Curriculum vitae
Barthold Philip (Bart) Schrier werd op 4 december 1964 geboren in
Vlaardingen. In 1983 behaalde hij het Atheneum diploma aan de
Rijksscholengemeenschap te Coevorden. Datzelfde jaar begon hij de studie
Geneeskunde aan de Rijksuniversiteit van Groningen. Het artsexamen werd
behaald in september 1992.
De dienstplicht werd vervuld als eerste luitenant-arts van de 42ste afdeling
Veldartillerie te Assen. Tijdens de dienstplicht werd hij beroepsmilitair,
bevorderd tot kapitein-arts, werkzaam als arts assistent urologie, onder leiding
van kolonel-arts P. Dik. In deze periode werd hij voor 6 maanden uitgezonden,
onder de vlag van de Multinational Force & Observers, naar de Sinaï te
Egypte, als geneeskundige steun bij de controle op het naleven van de Camp
David akkoorden.
In het kader van de opleiding voor Urologie, was hij gedurende 1996 en 1997
werkzaam op de afdeling Heelkunde van het Canisius Wilhelmina Ziekenhuis
in Nijmegen (opleiders: dr H.M.J. Joosten, later dr E.D.M. Bruggink). In 1998
tot medio 1999 werd het perifere deel van de urologische opleiding gevolgd in
de Isala klinieken locatie Sophia te Zwolle (opleider drs J.W. van Capelle).
Aansluitend werd het academische deel van de opleiding gevolgd tot eind 2001
in het Universitair Medisch Centrum, Sint Radboud te Nijmegen (opleider:
prof. dr F.M.J. Debruyne). Per 1 februari 2002 is hij werkzaam als uroloog in
het Jeroen Bosch Ziekenhuis, locatie Carolus te `s Hertogenbosch. In juni 2002
legde hij het examen van de European Board of Urology met goed gevolg af en
werd hiermee Fellow of the European Board of Urology.
Bart is getrouwd met Francien Miedema en samen hebben zij twee eeneiige
dochters, Frederique en Christien.
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Stellingen
behorende bij het proefschrift
Invasive bladder carcinoma
Prognostic assessment and therapeutic management
1. Patiënten met spierinvasief blaascarcinoom en een voorgeschiedenis
van oppervlakkige blaastumoren hebben een slechtere prognose dan
patiënten met primair spierinvasief blaascarcinoom. (Dit proefschrift)
2. De voorspellende waarde van p53 bij patiënten met progressief
oppervlakkig blaascarcinoom is beperkt. (Dit proefschrift)
3. Nachtelijke incontinentie bij patiënten met een ileum neoblaas kan
veroorzaakt worden door neoblaas contracties. (Dit proefschrift)
4. Fluimicil® verlaagt de viscositeit van slijm uit de ileum neoblaas. (Dit
proefschrift)
5. Bij patiënten met vergevorderd blaascarcinoom is met MRI na 2 kuren
chemotherapie betrouwbaar het resultaat van 6 kuren chemotherapie te
voorspellen. (Dit proefschrift)
6. MRI zal steeds belangrijker worden bij stadiëring van patiënten met
blaas- en prostaatkanker.
7. Een echte onderzoeker is een uitvinder met oog voor het onverwachte.
8. Een complicatie komt zelden alleen. (Wet van behoud van ellende)
9. Een uroloog met een handicap van 10 of lager werkt zelden fulltime.
10. Wie van de krenten wil genieten moet ook de pap verwerken.
11. Olwees bie sjure too bie in shu rait pleen, adderweis joe ar verrie, verrie,
verrie far vrom hoom. (Debruyne)
12. Mannen lijken vaak kleinzeriger dan vrouwen. Hier ligt mogelijk geen
lagere pijngrens, maar een intensere pijnbeleving aan ten grondslag.
13. Een rustend lid komt niet meer.
14. Iedere eikel weet dat glansshampoo niet voor hem is maar voor haar.
Uitnodiging
voor het bijwonen van de openbare
verdediging van mijn proefschrift
Invasive Bladder Carcinoma
Prognostic Assessment and Therapeutic
Management
dinsdag 26 september 2006
om 15.30 uur
in de Aula Major van de Radboud
Universiteit Nijmegen
Comeniuslaan 2 te Nijmegen
Receptie na afloop
ter plaatse
Bart Schrier
Prins Bernhardlaan 2
5251 EP Vlijmen
b.schrier@jbz.nl
Paranimfen:
Pieter Dik
p.dik@wkz.azu.nl
Eric van den Aker
e.v.d.aker@jbz.nl
Promotiefeest
Graag nodigen wij u en uw partner
uit voor een feest
ter gelegenheid van de promotie van
Bart Schrier
Op 29 september 2006
bent u
vanaf 20.30 uur
van harte welkom in de
ORANGERIE
St. Josephstraat 15a
te ’s-Hertogenbosch
De parkeergarage aan de
St. Josephstraat is vrij toegankelijk
voor gasten van het feest
RSVP voor 9 september
De paranimfen:
Pieter Dik
Aristoteleslaan 12
3707 EL Zeist
030 6916863
p.dik@wkz.azu.nl
Eric van den Aker
Burgemeester Vogelslaan 57
5062 KN Oisterwijk
013 5282743
e.v.d.aker@jbz.nl
